1

Anand Kumar MD

current Professor of Medicine (2014 - present) academic Section of Critical Care Medicine position Section of Infectious Diseases

Department of Medicine Department of Medical Microbiology Department of Pharmacology and Therapeutics University of Manitoba Winnipeg, Manitoba, Canada

Research Director, Section of Critical Care Medicine (2011-present) University of Manitoba Winnipeg, Manitoba, Canada

previous academic positions

1994-1996 Instructor, Section of Pulmonary and Critical Care Medicine Department of Medicine University of Wisconsin Hospital and Clinics Madison, Wisconsin

1996-2002 Assistant Professor of Medicine Section of Critical Care Medicine Section of Infectious Diseases Department of Medicine Rush University, Chicago, Illinois

1997-1998 Acting Director, CCM Fellowship Program Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

1996-2001 Associate Director, CCM Fellowship Program Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

2

2001-2005 Assistant Professor of Medicine Section of Critical Care Medicine Section of Infectious Diseases Department of Medicine Department of Medical Microbiology Department of Pharmacology and Therapeutics University of Manitoba Winnipeg, Manitoba, Canada

2003-2014 Associate Professor of Medicine Section of Critical Care Medicine Section of Infectious Diseases Cooper Hospital/University Medical Center University of Medicine and Dentistry, New Jersey Camden, New Jersey

education

1975-1980 Dunbarton High School, Pickering, Ontario, Canada valedictorian; top graduate Durham Region 1980 (22 high schools)

1980-1982 B.A. (incomplete) Faculty of Arts and Science, University of Toronto, Ontario, Canada

1982-1986 M.D., Faculty of Medicine, University of Toronto, Ontario, Canada

postgraduate training

1986-1987 Comprehensive Medical Internship Toronto General Hospital University of Toronto, Ontario, Canada

1987-1988 Internal Medicine Residency Year Two, Toronto General Hospital

1988-1989 Internal Medicine Residency Year Three, Toronto Western Hospital University of Toronto, Ontario, Canada

3

1989-1990 Critical Care Medicine Fellowship Year One, Health Sciences Centre and St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada 1990-1992 Critical Care Medicine Fellowship Year Two and Three Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA 1992-1993 Cardiovascular Research Fellowship Section of Cardiology and Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois, USA 1993-1994 Infectious Diseases Fellowship Year One (research) Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois, USA 1994-1996 Infectious Diseases Fellowship Year Two and Three (clinical) University of Wisconsin Hospital and Clinics Madison, WI, USA work experience 1988-1989 House Medical Officer (wards/CCU/MICU/SICU) Toronto East General Hospital, Toronto, Ontario, Canada 1988-1989 House Medical Officer and Casualty Officer (emergency/CCU/ICU), St. Joseph's Health Centre Toronto, Ontario, Canada 1989-1990 House Medical Officer (CCU/MICU/SICU) Health Sciences Center, Winnipeg, Manitoba, Canada 1989-1990 House Medical Officer (CCU/MICU/SICU) St. Boniface General Hospital, Winnipeg, Manitoba, Canada 1989-1990 Emergency Transport Physician, Provincial Air Ambulance

Winnipeg, Manitoba, Canada 1990-1991 Instructor -Clinical Methods for Year 2 students

4

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois August Instructor, Section of CCM/Faculty of Medicine 1991 University of Manitoba

Attending Staff, St. Boniface Hospital, Winnipeg, Manitoba, Canada August Attending Staff, Medicine and ICU, McKellar General Hospital 1992 Thunderbay, Ontario, Canada 1994-1996 Attending Staff and Instructor, Trauma-Life Support Unit University of Wisconsin Hospital and Clinics Madison, Wisconsin 1996-2001 Attending Physician

Section of Critical Care Medicine Department of Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois 1996-2001 Attending Physician, MICU Cook County Hospital Chicago, Illinois 2001-present Attending Staff MICU and SICU, Health Sciences Centre ICM and ICS, St. Boniface Hospital ICU, Concordia Hospital ICU, Grace Hospital Winnipeg, Manitoba, Canada 2004-present Director of Research, Critical Care Medicine University of Manitoba Winnipeg Manitoba board Diplomate of the National Board of Medical certification Examiners 1987 Licenciate of the Medical Council of Canada 1987 Diplomate of the American Board of Internal Medicine 1989

Fellow of the Royal College of Physicians and Surgeons (Canada) as Specialist in Internal Medicine 1990

Completion of Royal College accredited program in

5

Critical Care Medicine 1991 Board certified, Critical Care Medicine, American Board of Internal Medicine 1992 Board certified, Infectious Diseases American Board of Internal Medicine 1996 training Basic Cardiac Life Support (BCLS) Instructor certification American Heart Association 1981-1986 Advanced Cardiac Life Support (ACLS) Instructor American Heart Association 1987-1991

Fundamentals of Critical Care Support (FCCS) Instructor Society of Critical Care Medicine 1998-present medical Manitoba, Canada, #13-459 licensure New Jersey, USA, #25MA07704000

Wisconsin, USA (inactive) #35401 Ontario, Canada (inactive) #56799 Illinois, USA (inactive) #36080287 professional Fellow, American College of Critical Care Medicine organizations Fellow, American College of Chest Physicians

Member, Society of Critical Care Medicine Member, Canadian Critical Care Society

Member, Shock Society Member, Royal College of Physicians and Surgeons

(Canada) professional Critical Care Medicine, Infectious Diseases and Microbiology interests Sepsis and septic shock, Nosocomial infections research clinical studies :assessment of cardiovascular dysfunction in sepsis

and other critical illness using nuclear ventriculography and echocardiography

assessment of efficacy of antibiotic administration variables and other therapeutic modalities as predictors of outcome in an international cohort of 11000 cases of septic shock

6

characteristics of 2009 pandemic H1N1 influenza A infection

small animal projects –time dependent survival, cardiovascular physiology (echocardiography, conductance catheter techniques), transcriptional regulation (EMSA) and gene expression (gene array techniques) responses in murine models of septic shock using endotoxin and peritoneal implantation of an infected clot (with Aseem Kumar, PhD) differential endotoxin/cytokine release and hemodynamic effects in response to different classes and combinations of antibiotics in mouse and rat models of septic shock (clot implant)

bench laboratory projects -assessment of the effect of novel antimicrobial dosing strategies on bacterial clearance, cytokine generation, hemodynamic function and survival in a rodent model of E.coli peritonitis-induced septic shock assessment of novel antimicrobial dosing strategies on bacterial clearance and endotoxin generation in a in-vitro model of bacterial infection

role of TGF in blocking inflammatory myocardial dysfunction (time dependent effects on contractility, transcription factors and gene expression) and improving survival in septic shock

Graduate Amarnath Pisapati, PhD Microbiology (pending thesis completion) Students The use of ultra-high dose aminoglycoside in experimental rat

septic shock Noha Al-Kurdi, MSc Microbiology 2011

Antimicrobial pharmacodynamics against MRSA in an in vitro infection model: Comparing monotherapy to combinations under standard and altered conditions

Khalil Meghairbi, MSc Microbiology 2012

The association of antibiotic pharmacodynamic indices with survival in human septic shock

Ehsan Koohpayehzadeh, MSc pharmacology 2014 The effect of ultra-high doses of Gentamicin on resistant pathogenic bacteria in an in vitro pharmacodynamic model: A viable approach in life-threatening infections with septic shock

7

BSc Med Cheryl Peters, MD 2008 Students Initiation of inappropriate antimicrobial therapy results in a 5-fold

reduction of survival in human septic shock Laura Kravetsky, MD 2008 Combination antimicrobial therapy yields improved survival

compared to monotherapy in septic shock: A propensity-matched analysis

Harleena Gulati, MD 2005

Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock.

multicentre Principal Site Investigator. Multiple dose safety, tolerability, clinical studies pharmacokinetics and pharmacodynamics of PMX 622 in patients

with severe SIRS and evidence of infection. Novartis. 1997-1998

Sub-investigator - A Pivotal Phase II/III, multicenter, randomized, controlled, parallel group study of the HepaAssistTM Liver Assist System compared to standard SICU care in patients with acute hepatic failure. Circe Biomedical. 1996-1997

Member: Medic Trial, Clinical Evaluation Committee Elan Pharmaceuticals. 2000-2001. Principal Site Investigator (Health Sciences Centre, St. Boniface Hospital) Canadian Fungal Infection Survey: A Point Prevalence Study. Fujisawa and Co, 2004 Principal Site Investigator (Health Sciences Centre, St. Boniface General Hospital and Grace General Hospital, Winnipeg Manitoba). Phase III trial of EMD 20001 (LIPOS) in patients with severe sepsis and evidence of infection. GlaxoSmithKline. 2004-2006. Principal Site Investigator (St. Boniface Hospital, Winnipeg, MB) The ACCESS trial. A controlled comparison Eritoran tetrasodium and placebo in patients with severe sepsis. Eisai, Inc 2006-2009. Principal Site Investigator (Health Sciences Centre, Winnipeg, MB) Safety and efficacy of TAK -242 in adults with severe sepsis (Phase II/III trial). Takeda, Inc. 2006-2007.

8

Principal Site Investigator (Health Science Centre, Winnipeg, MB) PROWESS-SHOCK: A Randomized, placebo-controlled trial of Drotrecogin Alfa (Activated) for the treatment of septic shock. Eli Lilly Co. 2008-2011.

Chair, Clinical Evaluation Committee. ProBac: Use of Procalcitonin level as part of a decision tree to discontinue antibiotics when started empirically in the ICU in hemodynamically stable patients with no site of infection identified. Brahms AG, 2008-2009. Principle Site Investigator (Health Sciences Centre and St. Boniface Hospitals) Open-label, non-comparative study of intravenous anidulafungin followed optionally by oral voriconazole or fluconazole therapy, for treatment of documented candidemia/invasive candidiasis in intensive care unit patient ppulation. Pfizer and Co, 2009-present. Principle Site Investigator (Health Sciences Centre and St. Boniface Hospitals) Efficacy and safety of Eraxis/Ecalta (anidulafungin) compared to Cancidas (caspofungin) in patients with candida deep tissue infections: A phase 4 study. Pfizer and Co. 2009-2012. Principle Site Investigator (St. Boniface Hospital and Health Sciences Centre) The OASIS Study: Talactoferrin for the treatment of severe sepsis - a Phase II/III trial. Aggenix Co. 2010-2012 Principle Site Investigator (Health Sciences Centre and St. Boniface Hospital) CYTOFAB: Efficacy and safety of anti-TNF-alpha polyclonal antibody fragment (Fab) with placebo in adult patients with severe sepsis and/or septic shock. Astra-Zeneca Inc. 2010-2012 Steering Committee. Heparin anticoagulation to reduce death in septic shock: a multicentre interventional study. CIHR. 2012-present

academic J.W. Billes Open Admission Scholarship 1980-1984 honors Faculty of Arts and Science 1980-1982 Faculty of Medicine 1982-1984 University of Toronto Alpha Omega Alpha Medical Honor Society, 1983-1985

9

Young Investigator Award Shock Society 1993

Canadian Critical Care Society Arrow Young Investigator Award 1993 (best original research)

American Federation for Clinical Research

Trainee Investigator Award 1993 Robert M Kark Prize (best original research) Chicago Society of Internal Medicine 1993 Young Investigator Educational Scholarship Award (outstanding original research by a fellow or junior faculty) Society of Critical Care Medicine 1993

DuPont Pharmaceuticals/ACCP Young Investigator Award (outstanding research by a fellow)

American College of Chest Physicians 1993 DuPont Pharmaceuticals/ACCP Critical Care Research Award Finalist American College of Chest Physicians 1993 Cecile Lehman Mayer Award Finalist (best basic research presentation and manuscript) American College of Chest Physicians 1993 Internal Medicine Specialty Award (best research) Society of Critical Care Medicine 1994 American Federation for Clinical Research 1994 Trainee Investigator Award Canadian Critical Care Society Arrow Young Investigator Award 1994 (best original research)

In-Training Young Investigator Award (best abstract and manuscript by fellow or junior faculty)

Society of Critical Care Medicine 1995

Smith-Kline Beecham SHEA/CDC Hospital Epidemiology Training Program Scholarship 1996

Young Investigator Award

10

(best abstract and manuscript by faculty) Society of Critical Care Medicine 1998 Best Abstract, 2nd place As senior author (1st author John Ronald) Toronto Critical Care Medicine Symposium 2004 Soffer Award for best abstract nominee As senior author (1st author Sat Sharma) American College of Chest Physicians 2004 Internal Medicine Award (best abstract in Internal Medicine) Society of Critical Care Medicine 2005 Finalist, Best Abstract As senior author (1st author Ryan Zarychanski) Toronto Critical Care Medicine Symposium 2005 Finalist, Best Research As senior author (1st author Smita Pahkale) Society of Critical Care Medicine 2006 Winner, Infection Specialty Award As senior author (1st author Faisal Siddiqui) Society of Critical Care Medicine 2008

competitive Society of Critical Care Medicine Research Fellowship 1992 grant Effect of inflammatory cytokines on contractility and metabolism of support isolated cardiac myocytes ($50,000)

Medical Research Council of Canada Research Fellowship Award 1993-94. Role of inflammatory cytokines in human septic serum-induced depression of isolated cardiac myocytes ($50,000 renewable salary support) -renewal declined for 1994-95 Manitoba Medical Services Foundation Grant 2004 ($25,000) Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study Manitoba Medical Services Foundation, Winnipeg, Canada Lilly Sepsis Research Grant 2004 ($60,000): A retrospective review of a geographically comprehensive cohort of septic shock

11

patients from 1999-2003. Innovations and Opportunities Grant 2004 ($25,000) Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study Health Sciences Centre, Winnipeg, Canada Canadian Intensive Care Foundation Grant 2005 ($20,000) Continuous versus intermittent -lactam antibiotic infusion in severe sepsis: a randomized pilot study University of Manitoba Research Grant 2005 ($7500) Antibiotic PK/PD determinants of outcome in human septic shock. St. Boniface Hospital and Research Foundation 2005 ($30,000) Ultra high dose aminoglycoside therapy for experimental septic shock in mice and rats Health Sciences Centre Foundation 2005 ($35,000) A retrospective review of critical management-related determinants of outcome in septic shock Manitoba Health Research Council Establishment Grant 2008 ($100,000). Optimization and development of novel antimicrobial strategies for therapy of septic shock Public Health Agency of Canada. 2009-2010 ($350,000): Assessment of cytokine response and virus clearance in epidemic H1N1-associated critical illness Co-investigator, Canadian Institutes of Health Research. Catalyst Grant 2009-2011: Pandemic Outbreak Research Response ($600,000). Influenza-and H1N1-Related Critical Illness - Demand and Capacity in the Health Care System: the Canadian ICU Flu Study (PI Robert Fowler, MD) Co-investigator. Public Health Agency of Canada. 2009-2011 ($400,000): Influenza-and H1N1-Related Critical Illness - Demand and Capacity in the Health Care System: the Canadian ICU-Flu Study (Co-PIs, Robert Fowler and Dr. Philippe Jouvet). Co-investigator, Canadian Institutes of Health Research. Operating Grant 2011 ($228,000). Strategies for Protecting Vulnerable Canadian Populations from Emerging Infectious Diseases (PI, Syed Moghadas, PhD)

12

Co-investigator, Canadian Institutes of Health Research. Operating Grant 2011 ($100,000). Heparin anticoagulation to reduce death in septic shock (HADES pilot) (PI, Ryan Zarychanski, MD) Co-investigator, Manitoba Health Research Council. Operating Grant 2011 ($100,000). Heparin anticoagulation to reduce death in septic shock (HADES pilot) (PI, Ryan Zarychanski, MD) Co-investigator, Canadian Institutes of Health Research. Networks of Centers of Excellence Program 2012-2017 ($23,888,157). Technology Evaluation in the Elderly Networks (Tech Value Net). (PI, Daren Heyland)

other grants Merck Unrestricted Research Grant 1999 ($8000): Effect of

antibiotics selection on cardiovascular performance in a murine model of septic shock.

Pfizer Unrestricted Research Grant 2000 ($8000): Effect of antibiotics selection on survival in a murine model of septic shock. Ortho-McNeil Unrestricted Research Grant 2000 ($10,400): Effect of antibiotic selection on endotoxin and cytokine generation in a murine model of septic shock. ABbiodisk, Inc Grant 2004 ($5000 material support): Pharmacokinetic/pharmacodynamic indices predict outcome in human septic shock. Merck Unrestricted Research Grant 2004 ($10,000): Assessment of therapeutic determinants of outcome in a comprehensive cohort of septic shock. Pfizer Unrestricted Research Grant 2005 ($15,000): Assessment of therapeutic determinants of outcome in septic shock. Astellas Canada Unrestricted Research Grant 2005 ($10,000): Assessment of antimicrobial administration delay as a cause of excessive mortality in fungal septic shock. Astellas US Unrestricted Research Grant 2005 ($15,000): Assessment of antimicrobial administration delay as a cause of excessive mortality in fungal septic shock.

13

Bristol-Myers-Squibb Unrestricted Research Grant 2005 ($10,000): Effect of different resuscitative fluids and volumes on outcome in human septic shock. AstraZeneca Unrestricted Research Grant 2005 ($3500): Critical determinants of outcome in human septic shock. Bayer Unrestricted Research Grant 2005 ($10,000): Assessment of therapeutic determinants of outcome in human septic shock. Wyeth Unrestricted Research Grant 2006 ($12,500): Assessment of antimicrobial determinants of outcome in human septic shock. Pfizer Unrestricted Research Grant 2008 ($20,000): A propensity matched analysis of combination versus mono-antimicrobial therapy of septic shock. Pfizer Unrestricted Research Grant 2009 ($20,000): A retrospective review of a comprehensive cohort of fungal septic shock Roche Pharmaceuticals 2009 ($365,000): Relative oral bioavailability of oseltamivir in ill patients with respiratory failure in the intensive care unit: an investigator-initiated study. Roche Pharmaceuticals 2009-2011 ($3,250,000): A randomized, double-blinded controlled trial comparing high vs standard dose oseltamivir in severe influenza infection in the ICU: an investigator-initiated, multi-centre study. Collaborative Matching Support: Public Health Agency of Canada 2009-2011 Astellas Pharmaceuticals 2009 ($30,000): A retrospective review of a comprehensive cohort of septic shock. Assessment of critical determinants of outcome in Candida septic shock. Astellas Pharmaceuticals 2009-2012 ($120,000): A retrospective review of a comprehensive cohort of fungal septic shock. Impact of echinocandin therapy on outcome. Astellas Pharmaceuticals 2010-2011 ($70,000). Astellas Fellowship in Antifungal Research. Fellowship support for 1 year of research training for Shravan Kethireddy, MD Glaxo-Smith-Kline (GSK) 2011-2013 ($50,500). Severe pandemic H1N1 infection in ICU: Comparative resource utilization.

14

Glaxo-Smith-Kline (GSK) 2011-2013 ($50,000). Severe pandemic H1N1 infection in ICU: Pulmonary pathological disease progression in fatal H1N1 pneumonia Pfizer 2011-2012 ($20,000) Comparison of MRSA monotherapies to combinations under standard and septic shock infection site conditions in an in-vitro infection model

committees Class of 1986 (Medicine) representative to University of Toronto

Student Council 1985, Toronto, Ontario, Canada Toronto General Hospital Antibiotic Use Committee 1987 Toronto, Ontario, Canada

Graduate Medical Education Evaluation Committee, 1989-90 University of Manitoba, Winnipeg, Manitoba, Canada Director, Quality Assurance, Division of Cardiology/CCM Rush-Presbyterian-St. Luke’s Medical Center, 1996-2001 Nosocomial Pneumonia Process Improvement Committee Rush-Presbyterian-St. Luke’s Medical Center, 1996-1997 Society of Critical Care Medicine Research and Awards Committee, 1998-2000

Department of Medicine, Quality Assurance Committee 1999-2002 Rush-Presbyterian-St. Luke’s Medical Center Medical Care Evaluation Committee 1999-2001

Credentials Committee, 2001-2003 American College of Critical Care Medicine

American Board of Internal Medicine/Society of Critical Care Medicine Educational Project Committee 2002 Chairs: Donald Chafin, MD and Antoinette Spevetz, MD

Planning Committee, Rocky Mountain Critical Care Conference. Silver Star Mountain Resort, BC, Canada. February 19-22, 2003

Abstract Review Committee, Society of Critical Care Medicine Annual Scientific Symposium 2003-2010

15

Member, International Scientific Review Committee Eli Lilly Research Grants Program 2003-2004

Member, Continuing Education Committee, 2003-2005 Society of Critical Care Medicine Planning Committee, Rocky Mountain Critical Care Conference. Banff Resort, BC, Canada. February 17-20, 2004

Vice Chair, Credentials Committee, 2004 American College of Critical Care Medicine Chair, Credentials Committee, 2005-2007 American College of Critical Care Medicine Member, On-line Education Committee Society of Critical Care Medicine 2005-2007 Organizing Committee Public Health Agency of Canada Conference Severe H1N1 Disease: Preventing Cases; Reducing Mortality Sept 2-3, 2009, Winnipeg, MB

Physician Advisory Committee St. Boniface Hospital/Winnipeg Regional Health Authority 2010-present Antimicrobial Stewardship Committee Winnipeg Regional Health Authority 2010-present Organizational Committee De-escalation Symposium University of Manitoba, Sept 15, 2012 Sepsis Working Group (Information Systems Update) Winnipeg Regional Health Authority 2014-present Group Head, Infection Management

Surviving Sepsis Campaign International Guidelines for the Management of Severe Sepsis and Septic Shock 2016 Guideline Writing Committee 2014-present

16

course Fundamentals of Critical Care Support participation Rush-Presbyterian-St. Luke’s Medical Center

1997, 1998, 1999, 2000, 2001 University of Wisconsin at Madison 1999, 2000, 2001 Cadaveric Procedure Course University of Wisconsin 1995, 1996, 1997, 1998, 1999, 2000, 2001 Rush-Presbyterian-St. Luke’s Medical Center 2002 University of Manitoba 2003-2005 ad-hoc reviewer Critical Care Medicine Gastroenterology Chest JAMA Journal of Heart and Lung Transplantation Journal of Molecular and Cellular Cardiology American Journal of Physiology

Journal of Applied Physiology Clinical Infectious Diseases

American Journal of Respiratory and CCM Circulation Research Cytokine

Cardiovascular Research Journal of Applied Physiology Archives of Internal Medicine Annals of Internal Medicine Intensive Care Medicine Journal of Infectious Diseases Canadian Medical Association Journal (CMAJ) Annals of Emergency Medicine Journal of Infection BMC Immunology Annals of Emergency Medicine Scandinavian Journal of Infectious Diseases European Respiratory Journal Critical Care Thorax Journal of Critical Care Clinical Microbiology and Infection

17

original research manuscripts 1) Kumar A, Devlin HR, Vellend H: Pasteurella multocida meningitis in an adult: Case report and review. Reviews of Infectious Diseases 1990;12:440-448 2) Kumar A, Minuk G: Post-infantile giant cell hepatitis in association with hypereosinophilia. Gastroenterology 1991;101:1417-1419 3) Kumar A, Wong N, Bow E, Sutton D: Thrombotic thrombocytopenic purpura in association with human immmunodeficiency virus infection. Case report and review. Canadian Journal of Infectious Diseases 1992;3:37-41 4) Kumar A, Kamanpuhzha P: Pasteurella multocida septic arthritis. Southern Medical Journal 1992;85:329-331 5) Kumar A, Bleck T: Intravenous midazolam for the treatment of refractory status epilepsy. Critical Care Medicine 1992;20:483-488 6) Kumar A: Massive gastrointestinal hemorrhage due to esophageal candidiasis. Southern Medical Journal 1994;87:669-671 7) Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor- and interleukin-1 are responsible for depression of in-vitro myocardial cell contractility induced by serum from humans with septic shock. Journal of Experimental Medicine 1996;183:949-958 8) Goldfarb RD, Glock D, Kumar A, McCarthy RJ, Mei J, Guynn T, Matushek M, Trenholme G, Parrillo JE: A porcine model of peritonitis and bacteremia simulates human septic shock. Shock 1996;6:442-451. 9) Kumar A: Intravenous amiodarone for atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Southern Medical Journal 1996;89:779-785. 10) McGill M, Kumar A, Rahko P: Venous air embolism: Echocardiographic diagnosis of left-sided air bubbles in a patient with previously diagnosed intrapulmonary shunt. Chest 1997;111:826-828 11) Kahl BS, Kumar A, Hale SJ, Hart MN, Badr S: Hantavirus pulmonary syndrome in Wisconsin. Wisconsin State Medical Journal 1997;96:33-6 12) Kumar A, Parrillo JE: Divergent effects of epinephrine and amrinone on contractility

18

and cyclic AMP generation of TNF-exposed cardiac myocytes. Crit Care Med 1999;27:286-292. 13) Kumar A, Kandula P, Brar R, Dee L, Uretz E, Parrillo JE: The role of nitric oxide and cyclic GMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999;276:R265-R276. 14) Pahwa R, Kumar A: Persistent left superior vena cava: an intensivist's experience and review of the literature. Southern Medical Journal. 2003;96:528-9. 15) Paladugu B, Kumar A, Parrillo JE, Der S, Osman J, Mensing J, Falvo L, Kumar A: Bacterial DNA and RNA depress contractility of rat cardiac myocytes. Shock 2004;21:364-369 16) Kumar A, Anel A, Bunnell E, Zanotti S, Habet K, Haery C, Marshall S, Neumann A, Ali A, Kavinsky C, Parrillo JE: Preload-independent mechanisms are partially responsible for improved cardiac output following large volume saline infusion in normal volunteers. Critical Care 2004;8:R128-R136 17) Kumar A, Anel R, Bunnell E, Habet K, Neumann A, Wolff D, Rosenson R, Cheang M, Parrillo JE: Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers. Intensive Care Med 2004;30:1361-1369. 18) Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S, Neumann A, Ali A, Kavinsky C, Cheang M, Parrillo JE. PWP and CVP fail to predict ventricular filling volume, cardiac performance or the response to volume infusion in normal subjects. Crit Care Med. 2004:32;691-699 19) Kumar A, Bunnell G, Lynn M, Anel R, MD, Habet K, Neumann A, Cheang M, Parrillo JE: Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid A analogue, E5531. Chest 2004;126:860-867 20) Kumar A, Zanotti S, Bunnell G, Habet K, Anel R, Neumann A, Cheang M, Cutler D, Parrillo JE: Interleukin-10 administration blunts the pro-inflammatory cytokine and metabolic response without affecting hemodynamic response to endotoxin challenge in healthy volunteers. Crit Care Med 2005;33:331-340 21) Arabi Y, Kumar A, Wood KE, Flaten A: The feasibility of nitric oxide delivery with high frequency jet ventilation. Respirology 2005;10:673-677 22) Kumar Aseem, Kumar Anand, Michael P, Brabant D, Parissenti AM, Ramana CV Xu X, Parrillo JE: Human septic serum derived from patients undergoing sepsis activates transcription factors STAT1, IRF1, NF-B and induces apoptosis in human myocytes J

19

Biol Chem 2005;280:42619-26 23) Kumar Anand, Paladugu B, Haery C, Kumar Aseem, Symeoneides S, Taiberg, Osman J, Trenholme G, Opal S, Goldfarb R, Parrillo JE: Timing of antibiotic administration in relation to duration of hypotension is a critical determinant of survival in a murine model of E. coli septic shock: Association with serum lactate and inflammatory cytokines. Journal of Infectious Diseases 2006;193:251-8 24) Kumar Anand, Roberts D, Wood KE, Light RB, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar Aseem, Cheang M: Duration of hypotension prior to initiation of effective antimicrobial therapy is a critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596 25) Kumar Anand, Paladugu B, Mensing J, Kumar Aseem, Parrillo JE: Nitric oxide-dependent and –independent mechanisms are involved in TNFα-induced depression of cardiac myocyte contractility. Am J Physiol 2007;292:R1900-R1906. 26) Kumar Anand, Paladugu B, Kumar Aseem, Mensing J, Parrillo JE. Transforming growth factor-1 blocks in-vitro cardiac myocyte depression by tumor necrosis factor, interleukin-1 and human septic serum. Crit Care Med 2007:35:358-364. 27) Aarts MW, Brun-Buisson C, Cook DJ, Kumar A, Opal S, Rocker G, Smith T, Vincent J-L, Marshall JC: Antibiotic management of suspected nosocomial ICU-acquired infection: Does prolonged empiric therapy improve outcome? Intensive Care Med. 2007;33:1369-1378 28) Kumar Anand, Schupp E, Bunnell E, Ali A, Milcarek B, Parrillo JE: Cardiovascular response to dobutamine predicts outcome in severe sepsis and septic shock. Critical Care 2008;12:R35-R46 29) Falvo L, Michael P, Xu X, Parrillo JE, Omri A, Kumar Anand and Kumar Aseem. Human septic serum induced apoptotic gene expression profile in human myocytes. In Cell Apoptosis Research Progress (as a refereed paper) Editor: Robert H. Fenton pages 135-152, May 2008, Nova Publishing. 30) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A: Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med 2008;36:2973-2979 31) Tessier M, Michael P, Brabant D, Chilakamarti RV, Omri A, Saleh M, Parrillo JE, Kumar Anand and Kumar Aseem. Identification of factors in septic sera utilizing antibody arrays. In Recent Advances in Biochemical and Biophysical Research (as a refereed paper). Editor: Ramana V. Chilakamarti. pages 1-23, May 2008, Research Signpost.

20

32) Bagshaw S, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood W, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A, and the CATSS Database Research Group. Acute Kidney Injury in Septic Shock: Clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Medicine 2009:35:871-881. 33) Hussein S, Michael P, Parissenti A, Omri A, Kumar A, Parrillo JE and Kumar A. Characterization of human septic sera induced gene expression modulation in human myocytes. Int J Clin Exp Med 2009;2(2):131-48 34) Kumar A, Ellis P, Arabi Y, Roberts D, Light RB, Parrillo JE, Dodek PE, Wood G, Kumar A, Peters C, Chateau D and the CATSS Database Research Group. Initiation of inappropriate antimicrobial therapy results in a 5-fold reduction of survival in human septic shock. Chest 2009;136:1237-1248. 35) Kumar A, Zarychanski R, Pinto R, Cook D , Marshall J, Lacroix J , Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S , Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall R and Robert Fowler for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically Ill Patients with Novel Swine Origin Influenza Virus A/H1N1 Infection in Canada. JAMA 2009;302(17):1872-1879 36) Smetanin P, Stiff D, Kumar A, Kobak P, Zarychanski R, Simonsen N, Plummer F. Potential ICU ventilator demand/capacity mismatch due to novel pandemic (2009) H1N1 infection in Canada: Impact of a national vaccination strategy. Canadian Journal of Infectious Diseases 2009; 20(4):e114-e123. 37) Zarychanski R, Stuart TL, Doucette S, Elliot L, Kumar A, Kettner J, Plummer F. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010;182:257-64. 38) Mousavi N, Czarnecki A, Ahmadie R, Fang T, Kumar K, Lytwyn M, Kumar A, Jassal DS. The utility of tissue Doppler imaging for the noninvasive determination of left ventricular filling pressures in patients with septic shock. J Intensive Care Med 2010;25:163-167. 39) Freed DH, Henzler D, White CW, Fowler R, Zarychanski R, Hutchison J, Arora RC, Manji RA, Legare JF, Drews T, Veroukis S, Kesselman M, Guerguerian AM, Kumar A and the Canadian Critical Care Trials Group. Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) 2009 infection in Canada. Canadian Journal of Anesthesia 2010;57:240-7 40) Oluyom-Obi T, Avery L, Menticoglou S, Schneider C, Kumar A, Lapinsky S, Zarychanski R. Perinatal and maternal outcomes in critically ill obstetric patients with

21

pandemic H1N1 Influenza A. Journal of Obstetrics and Gynecology 2010;32(5):443–447 41) Stiff D, Kumar A, Kissoon N, Fowler R, Jouvet P, Skippen P, Smetanin P, Kesselman M, Veroukis S. Potential pediatric ICU demand/capacity mismatch due to novel H1N1 in Canada. Pediatric Critical Care Medicine 2011;12(2):e51-e57 doi: 10.1097/PCC.0b013e3181e2a4fe 42) Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisapati A, Ahern S, Kanji S, Rello J, Kumar A. Enteric absorption and pharmacokinetics of oseltamivir in pandemic H1N1 influenza (2009) associated critical illness. CMAJ 2010; 182:357-63.

43) Sood MM, Rigatto C, Zarychanski R, Komenda P, Sood AR, Bueti J, Reslerova M, Roberts D, Mojica J, Kumar A. Acute kidney injury in critically ill patients infected with pandemic H1N1 influenza A: Report from a Canadian province. Am J Kid Dis 2010;55:848-855

44) Jouvet P, Hutchison J, Pinto R, Menon K, Rodin R, Choong K, Kesselman M, Veroukis S, Dugas MA, Santschi M, Guerguerian A-M, Withington D, Alsaati B, Joffe A, Drews T, Skippen P, Rolland E, Kumar A, Fowler R, Canadian Critical Care Trials Group H1N1 Collaborative. Critical illness in children with influenza A/H1N1 2009 infection in Canada. Pediatric Critical Care Medicine 2010;11(5);603-9 45) Hajjar L, Mauad T, Galas FRBG, da Silva LFF, Dolhnikoff M, Trielli T, Almeida JP, Borsato MRL, Abdalla E, Pierrot L, Filho RK, Auler JOC Jr, Saldiva PHN, Hoff PM, Kumar A. Severe novel influenza A (H1N1) infection in cancer patients. Annals of Oncology 2010;21(12):2333-41 doi:10.1093/annonc/mdq254 46) Kumar A, Safdar N, Kethireddy S, Chateau D. The survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. Critical Care Medicine 2010;38:1651-1664 47) Kumar A, Zarychanski R, Light RB, Parrillo JE, Maki DG, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood W, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S and the CATSS Database Research Group. Combination antimicrobial therapy yields improved survival compared to monotherapy in septic shock: A propensity-matched analysis. Critical Care Medicine 2010;38:1773-1785 48) Keynan Y, Juno J, Meyers A, Ball TB, Kumar A, Rubinstein E, et al. Chemokine receptor 5 Δ32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16:1521-2 49) Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J, the SAFE TRIPS Investigators (including Kumar A). Resuscitation fluid use in critically ill

22

adults: an international cross sectional study in 391 intensive care units. Critical Care 2010;14:R185 50) Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. Impact of systemic or mucosal immunity to Adenovirus on ad-based Ebolavirus vaccine efficacy in guinea pigs. J Inf Dis 2011;204: S1032-S1042. 51) Brabant D, Michael P, Narain R, Saleh M, Kumar A, Parrillo JE, Kumar A. Sepsis-mediated cellular dysfunction is mediated by DFF-induced apoptosis. Biochemical and Biophysical Research Communications 2011;412:260-5 52) La D, Czarnecki C, El-Gabalawy H, Kumar A, Meyers A, Plummer FA, Luo M. Enrichment of KIR3DL1/S1 alleles and HLA-B Bw6 homozygotes among H1N1/09 ICU patients: an exploratory study. PLoS ONE 2011:6(12): e29200. doi:10.1371/journal.pone.0029200 53) Cinel I, Ark M, Kubat H, Karabacak T, Serinol H, Tamer L, CinelL, Oral U, Michael P, Hussein S, Dellinger P, Parrillo JE, Kumar A, Kumar A. Involvement of Rho kinase (ROCK) in the sepsis-induced acute lung injury. J Thorac Dis 2012;4(1):30-39. Aug 10. DOI: 10.3978/j.issn.2072-1439.2010.08.04 54) Graham RG, Liang B, Van Domselaar G, Bastien N, Beaudoin C, Tyler S, Kaplen B, Landry E, Kumar A, Drews S, Fonseca K, Steppan P, Van Caaseele P, Cole R, Garceau R, Savoie S, Butt K, Stead F, Hatchette TF, Charest H, Bangura H, Li Y. Nationwide Molecular Surveillance of Pandemic H1N1 Influenza A Virus Genomes: Canada, 2009. PLoS ONE. 2012;6(1): e16087. doi:10.1371/journal.pone.0016087 55) Olafson K, Zarychanski R, Kumar A. Sedation use in patients with respiratory failure associated with H1N1 infection: A comparison to respiratory failure due to bacterial pneumonia-related ARDS and other viral pneumonias. Annals of Pharmacotherapy 2012;46:9-20. DOI 10.1345/aph.1Q446.

56) Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger P, Sharma S, Penner C, Kramer A, Wood KE, Ronald J, Zarychanski R and The Co-operative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Activated Protein C and septic shock: A propensity-matched cohort study. Critical Care Medicine 2012:40;2074-2981.

57) Arabi YM, Dara SI, Memish Z, Al-Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, Lapinsky S, Feinstein D, Wood G, Dial S, Kumar A for the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Antimicrobial therapeutic determinants of outcomes in patients with cirrhosis-associated septic shock. Hepatology 2012:56;2305-2312

23

58) Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin Inf Dis 2012;54:1739-1746. 59) Bleiblo F, Michael P, Brabant D, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR. Journal of Thoracic Diseases 2012;4(2):114-125. 60) Funk D, Kumar A. Inhaled nitric oxide in patients with the acute respiratory distress syndrome secondary to Influenza A (H1N1) 2009 infection in Canada. Can J Anesthesia 2013;60(2);212-213 61) Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Vancomycin pharmacodynamics and survival in patients with methicillin–resistant Staphylococcus aureus (MRSA)–associated septic shock. International Journal of Antimicrobial Agents 2013: 41 (2013) 255– 260 62) Bleiblo F, Michael P, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. JAK Kinases are required for the bacterial RNA and poly I:C-induced tyrosine phosphorylation of PKR. International Journal of Clinical and Experimental Medicine 2013;6(1):16-25. 63) Bleiblo F, Michael P, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. STAT1 and STAT2 Null Cells are Resistant to Bacterial RNA-Induced Apoptosis Due to a Deficiency in the Constitutive and Inducible Activation of Apoptosis-Regulating Proteins. International Journal of Clinical and Experimental Medicine (in press) 64) Arabi YM, Dara SI, Tamim HM, Rishu AH, Bouchama A, Khedr MK, Feinstein D, Parrillo JE, Wood KE, Keenan S, Zanotti S, Martinka G, Kumar A, Kumar A and the CATSS Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: An international multicenter cohort study. Critical Care 2013;17:R72 65) Kethireddy S, Bruce Light RB, Miranejad Y, Maki D, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo JE, Kumar A for the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Mycobacterium tuberculosis septic shock. Chest 2013;144:474-82. 66) Muscedere J, Ofner M, Kumar A, Long J, Lamontagne F, Cook D, McGeer A, Chant C, Marshall J, Jouvet P, Fowler R for the ICU-FLU Group and the Canadian Critical Care Trials Group. The occurrence and impact of bacterial and fungal organisms complicating critical care illness associated with influenza A (H1N1) infection. Chest 2013;144:39-47.

24

67) Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar Aseem, Kumar Anand: The Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med 2014;189:1204-13. 68) Sood MM, Shafer LA, Ho J, Reslerova M, Martinka M, Keenan S, Dial S, Wood G, Rigatto C, Kumar A, and the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Early reversible acute kidney injury in septic shock is associated with improved survival. Journal of Critical Care 2014:29;711-717. 69) Sood M, Mandelzweig K, Rigatto R, Tangri N, Komenda P, Martinka G, Arabi Y, Keenan S, Kumar Aseem, Kumar Anand for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. The site of infection but not the etiologic pathogen is associated with the occurrence and severity of AKI in septic shock. Intensive Care Medicine 2014:40;1080-1088. 70) Beck V, Chateau D, Bryson GL, Pisapati A, Zanotti S, Parrillo JE, Kumar A. Timing of Vasopressor Initiation and Mortality in Septic Shock: A Cohort Study. Critical Care 2014: 2014:18:R97. 71) Waechter J, Kumar A, Lapinsky SE, Marshall J, Dodek PE, Arabi Y, Parrillo JE, Dellinger RP, Garland A. Interplay Between Fluids and Vasoactive Agents on Mortality in Septic Shock: A Multicenter, Observational Study. Crit Care Med 2014;42:2158-2168. 72) Funk D, Doucette S, Dodek PE, Marshall J, Kumar A. Low Dose Corticosteroid Treatment in Septic Shock: A Propensity Matching Study. Crit Care Med 2014;42:2333-2341. 73) Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hébert P, Cook DJ, Fergusson DA for the Canadian Critical Care Trials Group. The efficacy and safety of heparin in patients with sepsis: A systematic review and meta-analysis. Crit Care Med 2015;43;510-518. 74) Rimmer E, Houston BL, Kumar A, About-Setta AM, Friesen C, Rock G, Turgeon AF, Cook DJ, Houston DS, Zarychanski R. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: A systematic review and meta-analysis. Critical Care 2014;18:699. 75) Shojaei M, Parnell G, Booth D, Kumar A, Phu A, Huang H, Nalos M, McLean AS, McPhie K, O’Connor K, Schibeci S, Tang BM. IFI27 as a genomic marker of immune dysfunction in severe influenza infection. (submitted)

25

76) Jung J, Long J, Pinto R, Zarychanski R, Cook DJ, Jouvet P, Marshall JC, Kumar A, Rodin R, Fowler RA. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians (submitted) 77) Delaney JW, Burns KEA, Burry LD, Griesdale D, Hutchison J, Jouvet P, Kumar A, Lamontagne F, Long J, Marshall J, Mehta S, Menon K, Pinto R, Fowler RA. Corticosteroids in the treatment of Influenza A 2009 (H1N1pdm09)-related critical illness (submitted) 78) Bednarczyk JM, Kethireddy S, White CW, Freed DH, Singal R, Bell D, Ahmed SZ, Kumar A, Light B: Extracorporeal membrane oxygenation for blastomycosis related acute respiratory distress syndrome: a case series. Can J Anes 2015 (in press) 79) Fowler RA, Abdelmalik P, Wood G, Foster D, Gibney N, Bandrauk N, Turgeon AF, Lamontagne R, Kumar A, Zarychanski R, Green R, Bagshaw SM, Stelfox HT, Foster R, Dodek P, Shaw S, Granton J, Lawless B, Hill A, Rose L, Adhikari NK, Scales DC, Cook DJ, Marshall JM, Martin C, Jouvet P for the Canadian Critical Care Trials Group. Critical Care Capacity in Canada: Results of a National Cross-Sectional Study. Critical Care 2015 (in press). 80) Karvellas CJ, Abraldes JG, Arabi Y, Kumar A and the Cooperative Antimicrobial Theray of Septic Shock (CATSS) Database Group. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study. Alimentary Pharmacology and Therapeutics 2015 (in press). 81) Amaral ACKB, Fowler RA, Pinto R1, Rubenfeld GD, Ellis P, Bookatz B, Marshall J, Martinka G, Keenan S, Laporta D, Roberts D, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Patient and organizational factors associated with delays in antimicrobial therapy for septic shock (submitted). 82) Daneman N, Rishu AH, Xiong W, Bagshaw SM, Cook DJ, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler RA and the Canadian Critical Care Trials Group. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials 2015;16:173 edited volumes and books

26

1) Kumar A, Parrillo JE. Guest Editors, Critical Care Clinics. Historical Aspects of Critical Care Medicine and Critical Illness. Elsevier Saunders 2009;25(1) 2) Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Critical Care Medicine. April 2010;38(4) 3) Kumar A. Guest Editor, Critical Care Clinics. Optimizing Antimicrobial Therapy of Sepsis and Septic Shock. Elsevier Saunders 2011;27(1) 4) Kumar A. Guest Editor. Critical Care Clinics. Life-Threatening Infections I. Elsevier Saunders 2013;29(2) 5) Kumar A. Guest Editor. Critical Care Clinics. Life-Threatening Infections II. Elsevier Saunders 2013;29(3) chapters, invited reviews, editorials and letters 1) Section Editor, Infectious Diseases: Medical Council of Canada Qualifying Exam (MCCQE) Review Notes and Lecture Series 1986 (2nd edition). Editors, Mark C. Miller, George L. Kruzyk. University of Toronto Press 2) Contributing editor: Yearbook of Critical Care Medicine 1991 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 3) Contributing editor: Yearbook of Critical Care Medicine 1992 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 4) Kumar A, Parrillo JE: Clinical manifestations of cardiovascular dysfunction in sepsis. In Pathophysiology of Shock, Sepsis and Organ Failure. Editor: Gunther Schlag and Heinz Redl. Springer-Verlag Publications 1993 5) Contributing editor: Yearbook of Critical Care Medicine 1993 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 1993 6) Contributing editor: Yearbook of Critical Care Medicine 1994 Editors: JE Parrillo MD and M Rogers MD Mosby Yearbook Publications 1994 7) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. Editors: Roger Bone and Joseph

27

E. Parrillo. Mosby Publications 1995 8) Kumar A, Parrillo JE: Myocardial depression in septic shock: Role of nitric oxide and other mediators. In Proceedings of the Fourth Wiggers Bernard Conference on Shock, Sepsis, and Organ Failure. Editor: G Schlag and DL Traber. Springer-Verlag Publications 1995 9) Kumar A, Parrillo JE: Nitric oxide and the heart. In Update in Intensive Care and Emergency Medicine Volume 23: Role of nitric oxide in sepsis and ARDS. Series Editor: JL Vincent, Volume Editors: MP Fink and D Payen. Springer Verlag Publications 1995. 10) Kumar A: Management of infections in the immunosuppressed. In Critical Care Medicine: Perioperative Management. Editors: Michael J. Murray, Douglas B. Coursin, Ronal G. Pearl, and Donald S. Prough. Lippincott-Raven Press 1996. 11) Kumar A, Wood KE: Hypovolemic and hemorrhagic shock. In Current Therapy in Critical Care Medicine. Editor: JE Parrillo. Mosby Publications 1997. 12) Kumar A, Parrillo, JE: The heart in sepsis: The role of nitric oxide in septic myocardial depression. In Yearbook of Intensive Care and Emergency Medicine 1997. Editor: JL Vincent. Springer Verlag Publications 1997. 13) Kumar A: Central nervous system infections. In Society of Critical Care Medicine Board Review Manual 1997. Editor: J Zimmerman. SCCM Publications 1997. 14) Kumar A: Cardiovascular Pharmacology: Inotropes, vasopressors and vasodilators. In Society of Critical Care Medicine Board Review Manual 1997. Editor: J Zimmerman. SCCM Publications 1997. 15) Kumar A: Inotropes and gut mucosal perfusion: A brake on the motor of multiple organ failure? Crit Care Med 1997;25:1266-1267 16) Kumar A, Symoneides S: Life-threatening infections in the immunosuppressed. In Society of Critical Care Medicine Refresher Course Manual 1998. Editor: J Zimmerman. SCCM Publications 1998. 17) Contributing Editor: Fundamental Critical Care Support Course Text. Second Edition. A Standardized Curriculum of the Principles of Critical Care Medicine. Editors: RP Dellinger et al. Society of Critical Care Medicine Publications 1998. 18) Kumar A: Catheter related infections. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 1999.

28

19) Kumar A: Antimicrobials in the ICU: Beyond Bugs and Drugs. In Society of Critical Care Medicine Refresher Course Manual 1999. Editor: Pamela Roberts. SCCM Publications 1999. 20) Kumar A: Nosocomial and ventilator-associated pneumonia. In Society of Critical Care Medicine Refresher Course Manual 1999. Editor: Pamela Roberts. SCCM Publications 1999 21) Kumar Anand, Kumar Aseem, Parrillo JE: Cytokines and septic myocardial depression: Nitric oxide vs. Sphingosine/ceramide? Crit Care Med June 1999;27:1391-1393. 22) Kumar A, Short J, Parrillo JE: Genetic Factors in Septic Shock. JAMA 1999;282:579-581. 23) Kumar A: The dobutamine oxygen flux test: A road map to outcome in sepsis? Crit Care Med 1999;27:2571-2572. 24) Kumar A, Haery C, Parrillo JE: Cardiac manifestations of sepsis: Role of cytokines and nitric oxide. Critical Care Clinics of North America 2000;16:251-288. 25) Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock, Part I: Clinical manifestations of cardiovascular dysfunction in septic shock. Journal of Cardiothoracic and Vascular Anesthesia 2001;15:364-376. 26) Kumar A, Krieger A, Symoneides S, Parrillo, JE: Myocardial dysfunction in septic shock, Part 2: Role of cytokines and nitric oxide. Journal of Cardiothoracic and Vascular Anesthesia 2001:15;485-511 27) Landgarten MJ, Kumar A, Parrillo JE: Cardiovascular dysfunction in sepsis and septic shock. Current Treatment Options in Cardiovascular Medicine 2000;2:451-459. 28) Contributing editor: Yearbook of Critical Care Medicine 2001 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2001. 29) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 2nd Edition. Editors: Joseph E. Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2001. 30) Kumar A, Krzyda E, Darovic GO: Chapter 13: Infusion-related sepsis. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3rd Ed. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002.

29

31) Kumar A, Darovic GO: Chapter 8: Establishment of Central Venous Access. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3rd Ed. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002. 32) Darovic GO, Kumar A: Chapter 9: Monitoring Central Venous Pressure. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 3rd Ed. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2002. 33) Anel R, Kumar A: Fungal Infections and Resistance. In Society of Critical Care Medicine Refresher Course Manual 2001. Editor: P Roberts. SCCM Publications 2001. 34) Hota B, Kumar A: Management of infections in the immunocompromised. In Critical Care Medicine: Perioperative Management. 2nd Edition. Editors: Michael J. Murray, Douglas B. Coursin, Ronald G. Pearl, and Donald S. Prough. Lippincott, Williams and Wilkins, 2002. 35) Kumar A, Calvin J, Parrillo JE: Critical Care Research. In Critical Care Medicine: Perioperative Management. 2nd Edition. Editors: Michael J. Murray, Douglas B. Coursin, Ronald G. Pearl, and Donald S. Prough. Lippincott, Williams and Wilkins 2002. 36) Zanotti S, Kumar A: Primum (non nocere) lavate manus. Critical Care Medicine 2001;29:458-459. 37) Osman J, Kumar A: Septic myocardial depression: No "no" to NO? Critical Care Medicine 2001;29:202-203. 38) Anel R, Kumar A: Experimental and emerging therapies for sepsis and septic shock: Part 1. Coagulation modulators, NO inhibitors, complement and steroids. Expert Opinion in Investigational Drugs 2001;10:1471-1485. 39) Zanotti S, Kumar Aseem, Kumar Anand:.Experimental and emerging therapies for sepsis and septic shock: Part 2. Cytokine modulation in sepsis and septic shock. Expert Opinion in Investigational Drugs 2002;11:1061-1075. 40) Manocha S, Feinstein D, Kumar Aseem, Kumar Anand: Experimental and emerging therapies for sepsis and septic shock: Part 3. Anti-endotoxin strategies in gram-negative sepsis and septic shock. Expert Opinion in Investigational Drugs 2002;11:1795-1812. 41) Contributing editor: Yearbook of Critical Care Medicine 2002 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2002.

30

42) Krishnagopalan S, Kumar Aseem, Parrillo JE, Kumar Anand: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002;8(5):376-388. 43) Court O, Kumar Aseem, Parrillo JE, Kumar Anand: Myocardial dysfunction in the septic patient. Critical Care 2002;6:500-508. 44) Kumar Aseem, Kumar Anand: IL-1 gene cluster polymorphisms: All in the family. Critical Care Medicine 2002;30:1168-1169. 45) Kumar Anand, Kumar Aseem, Parrillo JE: Reversible myocardial depression: A ubiquitous phenomenon in critical illness? Critical Care Medicine 2002;30:1392-1393. 46) Coursin DB, Ketzler, JT, Kumar A, Maki DG. Bioterrorism May Overwhelm Medical Resources. Anesthesia Patient Safety Foundation Newsletter. 2002;17(1):4-8. 47) Kumar A, Darovic G: Catheter related infections. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 2003. 48) Darovic G, Kumar A: Monitoring central venous pressure. In Handbook of Hemodynamic Monitoring. Editors: Gloria Darovic, R.N. and Corey Franklin, M.D. W.B. Saunders 2003. 49) Kumar A, Parrillo JE: Myocardial depressant substances in meningococcal septic shock. Critical Care Medicine 2002;30:2379-2380. 50) Kumar Anand, Kumar Aseem: Endotoxemic myocardial depression: A novel iNOS suppressing effect of albumin. Critical Care Medicine 2003;31:324-326. 51) Guest editor: Yearbook of Critical Care Medicine 2003 Editors: RP Dellinger MD, JE Parrillo MD, RA Balk MD, JE Calvin MD, Cory Franklin MD and BA Shapiro MD. Mosby Yearbook Publications 2004. 52) Kumar A, Wood KE, Parrillo JE: Circulating substances and energy metabolism in septic shock. Critical Care Medicine 2003;31:632-633 53) Sharma S, Kumar A: Septic shock, respiratory distress and multiple organ failure. Current Opinion in Pulmonary Medicine. 2003;9:199-209. 54) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2004 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2005 55) Wong J, Kumar A: Myocardial depression in sepsis and septic shock. In: Sepsis. Editors: Ortiz-Ruiz G, Perafan MA, Faist E, Castell CD. Springer-Verlag Inc, 2006

31

56) Ronald J, Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2004. Editor: David Porembka. SCCM Publications 2004. 57) Kumar A, Nasraway S: Sepsis and septic shock: Optimizing outcome. In Society of Critical Care Medicine Board Review Manual 2004. Editor: David Porembka. SCCM Publications 2004. 58) Taiberg L, Wong J, Kumar A: Myocardial depression in sepsis and septic shock. Advances in Sepsis 2004;4:82-94 59) Kumar A: Leukocyte lysozyme: A novel cause of septic myocardial depression? Crit Care Med 2004;32:304-305. 60) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2005 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2006 61) Brabant D, Ramana CV, Michael P, Tonnos M, Tessier T, Kung S, Kumar A, Kumar A: Molecular biology of sepsis. Proceedings of the International Biotechnolgy Symposia. Haldia Institute of Technology,India. Jan 15, 2005 62) Anel R, Kumar A. Human endotoxemia and human sepsis: Limits to the model. Critical Care Forum 2005;9:151-152 63) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2005. Editor: David Porembka. SCCM Publications 2005. 64) Kumar A, Nasraway S: Sepsis and septic shock: Optimizing outcome. In Society of Critical Care Medicine Board Review Manual 2005. Editor: David Porembka. SCCM Publications 2005. 65) Kumar A: Pathophysiology of septic shock. SCCM On-line repository 2005 (http://ricu.sccm.org/Security/LectureHome.aspx?LectureID=ee936f0f-d7d7-489b-940e-b3caf9a25bc2) 66) Kumar A: Shock. SCCM On-line repository 2005 (http://ricu.sccm.org/Security/LectureHome.aspx?LectureID=b176837c-259d-472f-8a13-cd4217f4c7a9) 67) Kumar Anand, Kumar Aseem. Nitric oxide and inflammatory cytokines in the heart: The presence of positive feedback loops. Critical Care Med 2005;33:2851-2. 68) Kumar A. Myocardial depression in sepsis and septic shock. Kuwait Medical Journal 2005:37:238-247

32

69) Kumar A, Parrillo JE: Myocardial Depression in Sepsis and Septic Shock. In 26th International Symposium on Intensive Care and Emergency Medicine, Yearbook of Intensive Care and Emergency Medicine. Editor, JL Vincent. Springer Verlag Publications 2006. 70) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2006. Editor: Michael Ivy. SCCM Publications 2006. 71) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2006 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2007 72) Kumar A. Pathophysiology of Shock. In Anesthesia Science. Editor N Webster. Blackwell Publishing Ltd, Oxford, UK 2007. 73) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2007. Editor: James E. Szalados. SCCM Publications 2007. 74) Kumar A: Implication of early diagnosis of infection on antimicrobial therapy. In Sepsis Handbook: Early Diagnosis of Sepsis. Editors: Phil Dellinger, Jean Carlet. Biomerieux Publications 2007 75) Kumar A, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 3nd Edition. Editors: Joseph E. Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2007. 76) Kumar Anand, Kumar Aseem, Parrillo JE: Myocardial dysfunction in sepsis and septic shock. In Textbook of Acute Heart Failure Syndromes: A Practical Approach for Physicians. Editors, Alexandre Mebazaa, Mihai Gheorgehiade, Falez Zannad, Joseph Parrillo and Wendy Gattis Stough. Springer-Verlag Ltd 2008. 77) Kumar A: Chapter 15: Infusion-related sepsis. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 78) Kumar A, Darovic GO: Chapter 8: Establishment of Central Venous Access. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 79) Darovic GO, Kumar A: Chapter 9: Monitoring Central Venous Pressure. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 80) Darovic GO, Zarychanski R, Kumar A: Chapter 10: Pulmonary Artery Pressure Monitoring. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009.

33

81) Dickieson A, Darovic GO, Kumar A: Chapter 11: Monitoring Cardiac Output. In Hemodynamic Monitoring: Invasive and Non-invasive Clinical Application. 4th Edition. Editor: Gloria Oblouk Darovic, RN. WB Saunders 2009. 82) Kumar Anand, Kumar Aseem: Development of sepsis therapeutics and molecular diagnostics. Expert Commentary Nova Publishing 2008. 83) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2007 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2008 84) Kumar Anand, Kumar Aseem: Sepsis and Septic Shock. In Civetta, Taylor and Kirby’s Critical Care. 4th Ed. Editors, A Gabrielli, Layon J, Yu M. Lippincott, Williams and Wilkin Co. 2008 85) Kumar A: Myocardial depression in sepsis and septic shock. Recent Advances in Biochemical and Biophysical Research, Editors: R. Chilakamarti, A. Kumar and R. Enelow, publisher: Research Signpost 2008. 86) Sharma S, Kumar A: Antimicrobial Management of Serious Infections. Guest Editor, Michell Levy, MD. Pulmonary Clinics of North America 2008;29(4):677-687. 87) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2008 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2009 88) Balk R, Kumar A: Severe pneumonia in the ICU. In Society of Critical Care Medicine Board Review Manual 2008. Editor: James E. Szalados. SCCM Publications 2008. 89) Kumar A: Antimicrobial management of sepsis and septic shock. In Society of Critical Care Medicine Refresher Course Manual 2008. Editor: Christina Rehm. SCCM Publications 2008. 90) Kumar A, Parrillo, JE: Preface. Historical Aspects of Critical Care Medicine and Critical Illness. Critical Care Clinics 2009;25(1): xii-xiv 91) Manji R, Wood KE, Kumar A: Evolution and History of Circulatory Shock. Critical Care Clinics 2009;25(1):1-29 92) Funk K, Parrillo JE, Kumar A: History of Septic Shock. Critical Care Clinics 2009;25(1):83-101 93) Funk D, Sebat F, Kumar A: A Systems Approach to the Early Recognition and Rapid Administration of Best Practice Therapy in Sepsis and Septic Shock. Current Opinion in Critical Care. 2009;15:301-307

34

94) Kumar A: Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Critical Care Clinics 2009; 25:733-752 95) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2009 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2010 96) Kumar A: Antimicrobial Therapy in Sepsis and Life-threatening Infection. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 97) Kumar A: Infections in the Immunosuppressed. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 98) Kumar A: Multiresistant Infections in the ICU. In Society of Critical Care Medicine Board Review Manual 2009. Editor: Christina Rehm. SCCM Publications 2009. 99) Zarychanski R, Kumar A. Early intravenous unfractioned heparin-also beneficial in acute lung injury? Response to letter. Crit Care Med 2009;37:1534 100) Gin A, Kumar A, Zarychanski R, Honcharik N. Increased sedative use in H1N1 patients in ICU. CMAJ 2009;181(8):500 101) The InFACT Global H1N1 Collaborative. InFACT: a global critical care research response to H1N1. Lancet November 10, 2009 DOI:10.1016/S0140-6736(09)61792-X 102) Clinical Guidance for the Management of Influenza-Like Illness in the Context of Pandemic H1N1 Influenza Virus in Adult Intensive Care Units. http://www.canadiancriticalcare.org/ICU_Guidelines_English.pdf. Public Health Agency of Canada. 2009 103) Ramsey CR, Miller RR, Funk D, Kumar A. Ventilator management for hypoxemic respiratory failure attributable to H1N1 novel swine origin influenza virus. Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Critical Care Medicine 2010;38(4):e58-e65. doi:10.1097/CCM.0b013e3181cde600 104) Funk D, Siddiqui F, Wiebe K, Miller RR, Bautista E, Jimenez E, Webster K, Kumar A. Practical lessons from the first outbreaks: Clinical presentation, obstacles, and management strategies for severe pandemic (H1N1) 2009 influenza pneumonitis. Kumar A, Farmer C. Guest Editors. H1N1 Novel Influenza: Pandemic Issues for Critical Care Practitioners. Critical Care Medicine 2010;38(4):e30-e37.doi: 10.1097/CCM.0b013e3181d10522 105) Fowler R, Jouvet P, Christian M, Kumar A. Critical illness due to influenza A 2009 H1N1. Critical Care Rounds. Oct 2009

35

106) Funk D, Zubert S, Kumar A. Antibiotics in sepsis and septic shock: Like everything else in life, timing is everything. Critical Care Medicine 2009:38:1211-1212. 107) Manji RA, Kumar A. Determining relevant cortisol concentrations in critically ill patients. Critical Care 2010:14:113 108) Ramsey C, Fowler R, Kumar A. Mechanical ventilation in critically ill patients with 2009 influenza A(H1N1)—Reply. JAMA 2010:303;940 109) The Writing Committee of the World Health Organization (WHO) Consultation on Clinical Aspects of Pandemic Influenza (H1N1) 2009. Clinical aspects of pandemic influenza A (H1N1) 2009. N Engl J Med 2010:362:1708-1719. 110) Opal S, Kumar A. Influenza. Textbook of Critical Care (6th ed) Fink MP, Abraham E, Vincent J-L, Kochanek PM Philadelphia, PA: Elsevier Saunders 2011 111) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2010 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2011 112) Kumar A. Early antimicrobial therapy in severe sepsis and septic shock. Current Infectious Diseases Reports 2010; 12:336–44. 113) Funk D, Kethireddy S, Kumar A. Improving outcomes in sepsis and septic shock: Getting it right the first time. In Sepsis Management: PIRO and MODS. Editors: Rello J, Lipman J, Lisboa T. Springer-Verlag 2010. 114) Kumar A, Safdar N, Kethireddy S, Chateau D. Odds ratios are contingent on event rates-Reply. Crit Care Med 2010; 38; 2426-27. 115) Kumar A and the CATSS Database Group. Mono- or combination- antibiotic therapy for septic shock? An epistemological dilemma-Reply. Crit Care Med 2010;39:423-4. 116) Ramsey C, Kumar A. H1N1: Viral pneumonia as a cause of acute respiratory distress syndrome. Current Opinion in Critical Care 2011: 17:64–71. 117) Kumar A. Preface. Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Critical Care Clinics 2011:27:xi-xii. 118) Funk D, Kumar A. Antimicrobial therapy for life-threatening infections: Speed is life. Critical Care Clinics 2011:27: 53-76. 119) Abad CL, Kumar A, Safdar N. Antimicrobial therapy of sepsis and septic shock: When are two drugs better than one? Critical Care Clinics 2011;27 (on-line only).

36

120) Kumar A. A) One size fits all & never change a winning team? –the need for balanced strategies in antibiotic therapy B) Combination therapy for septic shock--considerations for antibiotic stewardship. C) Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis- Reply. Crit Care Med 2011; 39:609. 121) Rahman O, Kumar A. Case study of pandemic H1N1 infection. Preparing Your ICU for an Effective Disaster Response. Editors, Wax R, Farmer C. SCCM Publications 2011 122) Kumar A, Jouvet P, Christian M, Fowler R. Pandemic H1N1 influenza. Current Concepts in Critical Care 2011. SCCM Publications 2011. 123) Anel R, Kumar A. Bacteremia, sepsis and septic shock. In Enfermedades Infecciosas (Infectious Diseases). Editors: Vesga O, Velez LA, Leiderman E, Restrepo A. Corporación para Investigaciones Biológicas (CIB)'s Editorial Fund 2011 124) Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): Speed is life. J Antimicrob Chemo 2011; 66:959-63. 125) Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Critical Care Nursing Clinics of North America 2011;23:79-97 126) Kumar A. A potential selection bias in the study of early combination antibiotic therapy versus monotherapy in septic shock: Reply. Crit Care Med 2011;39;1604-5 127) Patel GP, Kumar A. Antibiotics, antifungal and antivirals. Adult Comprehensive Critical Care Review Textbook 2011. Editor: Mathew Ferris, MD. SCCM Publications. 128) Kumar A. Pandemic H1N1 influenza. J Thorac Dis 2011;3:262-270. DOI: 10.3978/j.issn.2072-1439.2011.08.05 129) Kumar A, Maki D: Donor infection issues. In Management of the Potential Organ Donor Initiative. Editor: Kenneth E. Wood, DO. United States Health and Human Services 2013 (in press) 130) Kumar. Preface. Shock: Identification and Treatment. Editor: Rita Galeiras. A Coruña Hospital Complex. Galicia Healthcare Region (Spain) 2012 131) Kethireddy S, Kumar A. Infections in the immunosuppressed and immunocompromised. Comprehensive Critical Care Review: Adult. Editors, Pamela Roberts and S.R. Todd. SCCM Publications 2012

37

132) Kethireddy S, Kumar A. Antimicrobial De-escalation: Ehrlich’s Mandate Revisited. Current Concepts in Adult Critical Care. Editor, Eugene Cheng. SCCM Publications 2012. 133) Guest Editor: Infectious Diseases in Yearbook of Critical Care Medicine, 2011 Editors: RP Dellinger MD, JE Parrillo MD. Mosby Yearbook Publications 2012 134) Bleiblo F, Michael P, Brabant D, Ramana CV, Tai TC, Saleh M, Parrillo JE, Kumar Anand, Kumar Aseem. The Role of Immunostimulatory Nucleic Acids in Septic Shock. International Journal of Clinical and Experimental Medicine 2012;5(1):1-23. 135) Michael P, Bleiblo F, Kumar Anand, Kumar Aseem. Not only a toll for viruses: the role of toll-like receptor 3 in nonviral sepsis-induced cardiac depression. Crit Care Med 2012;40:2514-2515 136) Kethireddy S, Kumar A. Mortality due to septic shock following early, appropriate antibiotic therapy: Can we do better? Crit Care Med 2012:40;2228-2229 137) Funk D, Jacobsohn E, Kumar A. The role of the venous return in critical illness and shock. Part I: Physiology. Critical Care Medicine 2013:41;255-262 138) Funk D, Jacobsohn E, Kumar A. The role of the venous return in critical illness and shock. Part II: Shock and mechanical ventilation. Critical Care Medicine 2013:41; 573-579 139) Funk D, Kumar A. If the central venous Pressure Is [x], call me … maybe. Critical Care Medicine 2013;41:1823-1824. 140) Kumar A, Unligil U, Parrillo JE: Shock: Classification, pathophysiology, and approach to management. In Textbook of Critical Care Medicine. 4th Edition. Editors: Joseph E. Parrillo, MD and R. Phillip Dellinger, MD. Mosby Publications 2013. 141) Kethireddy S, Kumar A. Trending the fever curve. What does it tell us? Critical Care Medicine 2013;41:2034-2036 142) Rimmer E, Kumar A, Zarychanski R. Effectiveness of Human Recombinant Activated Protein C for Severe Sepsis and Septic Shock in Adult and Pediatric Patients: Randomized Clinical Trial Versus Nonrandomized Study. Reply by authors to letter. Crit Care Med 2013;41:e139-40 143) Ramsey C, Kumar A. Influenza and endemic viral pneumonia. Critical Care Clinics 2013;29:1069–1086 144) Kethireddy S, Darovic G, Kumar A. Catheter-related infections and sepsis. Crit Care Clinics 2013;29:989–1015.

38

145) Kumar A. An alternate pathophysiologic paradigm of sepsis and septic shock: Implications for optimizing antimicrobial therapy. Virulence 2014;5:80–97 146) Michael P, Brabant D, Bleiblo F, Ramana CV, Rutherford M, Tai TC, Kumar A, Kumar A. Influenza A-induced cellular signal transduction pathways. J Thoracic Dis 2013; 5(Suppl 2): S132–S141. 147) Kumar A: Preface. Life-threatening Infections I. Critical Care Clinics 2013;29(2): xiii-xiv 148) Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar Aseem, Kumar Anand Trends in infection source and mortality among patients with septic shock. Response to letter Am J Resp Crit Care 2014;190:710. 149) Kumar A: Antimicrobial delay and outcome in severe sepsis. Letter re: Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Critical Care Medicine 2014;42:e802 150) Liang S, Kumar A. Optimizing antimicrobial therapy in the ICU (3rd Ed). In Handbook of ICU Therapy. Eds Fuller J, Granton J, McConachie. Cambridge University Press 2014. London, England. 151) Funk D, Kumar A. Ebola Virus Disease: Update for Anesthesiologists. Canadian Journal of Anesthesia 2015;62:80-91 152) Vasquez-Grande G, Kumar A: Optimizing antimicrobial therapy of sepsis and septic shock: Focus on antibiotic combination therapy. Seminars in Respiratory and Critical Care Medicine 2015;36:154–166. 153) Opal S, Kumar A: Influenza. Textbook of Critical Care (7th ed) Fink MP, Abraham E, Vincent J-L, Kochanek PM Philadelphia, PA: Elsevier Saunders 2015 154) Karvellas D, Kumar A. Letter: What else can improve survival in cirrhotic patients with spontaneous bacterial peritonitis and associated septic shock? - authors' reply. Alimentary Pharmacology and Therapeutics 2015 (in press) 155) Liang S, Kumar A: Empiric antimicrobial therapy in septic shock: Optimizing pathogen clearance. Current Infectious Diseases Reports 2015 (in press) 156) Zarychanski R, Kumar A: Letter: What is the best heparin to treat sepsis with? Authors’ reply. Critical Care Medicine 2015 (in press).

39

abstracts 1) Feigenbaum A, Kumar A, Weksberg R: Singleton-Merten Syndrome: Autosomal dominant transmission with variable expression. American Journal of Human Genetics 1988;43(3):A48 #190 (suppl) 2) Kumar A, Dimou C, Hollenberg SM, Cunnion RE, Lawrence M, Uretz E, Snell RJ, Parrillo JE: Tumor necrosis factor produces a concentration dependent depression of myocardial cell contraction in-vitro. Clinical Research 1991;39(2):321A 3) Marantz S, Kumar A, Parker S, Alfa M, Kepron W, Lertzman M, Light RB: Quantitative cultures of endotracheal aspirates, bronchoalveolar lavage fluid, and bronchoscopic protected brush specimens in the diagnosis of pneumonia in intubated patients. Clinical and Investigative Medicine 1991;14(4):A22 (suppl) 4) Kumar A, Dimou C, Hollenberg SM, Cunnion RE, Lawrence M, Uretz E, Parrillo JE: Tumor necrosis factor produces depression of myocardial cell contraction in-vitro. Critical Care Medicine 1992;20(4):S52 (suppl) 5) Kumar A, Thota V, Dimou C, Olson J, Uretz E, Parrillo JE: Mechanism of tumor necrosis factor-induced myocardial cell depression in-vitro. Clinical Research 1992;40(2):293A 6) Kumar A, Dimou C, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor produces depression of cardiomyocyte shortening in-vitro: Clinical and Investigative Medicine 1992;15(4):A27 #151 (suppl) 7) Kumar A, Thota V, Dimou C, Olson J, Uretz E, Parrillo JE: Mechanism of tumor necrosis factor-induced myocardial cell depression in-vitro. Clinical and Investigative Medicine 1992;15(4):A27 #152 (suppl) 8) Kumar A, Bell D: Intravenous amiodarone for the treatment of rapid atrial fibrillation and flutter in the critically ill. Chest 1992;102(2):128S (suppl) 9) Kumar A, Thota V, Bunnell E, Olson J, Uretz E, Parrillo JE: Effect of inotropes on tumor necrosis factor-induced cardiomyocyte depression in-vitro. Chest 1992;102(2):88S (suppl) 10) Kumar A, Thota V, Olson J, Uretz E, Parrillo JE: Effect of nitric oxide synthetase inhibition on tumor necrosis factor induced myocardial cell depression in-vitro. JACC

40

1993;21:477A (suppl) 11) Rodriguez ER, Mientus TF, Ariztia EV, Kumar A, Parrillo JE: The inducible form of nitric oxide synthase is up-regulated by endotoxin treatment of cultured rat cardiac myocytes. JACC 1993;21:374A (suppl) 12) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Dee L, Stolz U, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression in-vitro is mediated by nitric oxide generation. Critical Care Medicine 1993;21:S278 13) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression in vitro is not a cyclic AMP dependent process. Clinical Research 1993;41:198A 14) Kumar A, Thota V, Ginsburg B, Dee L, Olson J, Kim J, Uretz E, Parrillo JE: Supernatants of endotoxin stimulated THP-1 cells depress myocardial cell contractility in-vitro. Clinical Research 1993;41:140A 15) Kumar A, Kosuri R, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Effect of nitric oxide synthetase inhibition on human septic serum-induced myocardial cell depression in-vitro. Circulatory Shock 1993;Suppl 2:22 #62 16) Kumar A, Kosuri R, Kandula P, Thota V, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced cardiomyocyte depression is not a cyclic AMP dependent process. Clinical and Investigative Medicine 1993;16:B42 #256 17) Kumar A, Kosuri R, Thota V, Dee L, Olson J, Uretz E, Parrillo JE: Nitric oxide and cyclic GMP generation mediates human septic serum-induced in-vitro cardiomyocyte depression. Chest 1993;103(2):12S (suppl) 18) Kumar A, Kosuri R, Thota V, Olson J, Dee L, Stolz U, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Circulation 1993;88:I617 #3320 (suppl) 19) Kumar A, Kosuri R, Ginsburg B, Dee L, Kim J, Olson J, Uretz E, Casey L, Parrillo JE: Myocardial cell contractility is depressed by supernatants of endotoxin stimulated THP-1 cells. Critical Care Medicine 1994;22:A118 20) Kumar A, Kosuri R, Dee L, Olson J, Uretz E, Parrillo JE: Selective immunoabsorption of IL-1 and TNF abrogates the in-vitro cardiomyocyte depressant effect of human septic serum. Critical Care Medicine 1994;22:A118 21) Kumar A, Kosuri R, Kandula P, Kandula P, Olson J, Dee L, Olson J, Uretz E, Parrillo JE: Tumor necrosis factor-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1994;22:A191

41

22) Kumar A, Kosuri R, Kandula P, Olson J, Uretz E, Parrillo JE: Cardiomyocyte depression induced by human septic serum is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1994;22:A119 23) Schupp E, Kumar A, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: The cardiovascular response to incremental doses of dobutamine in septic shock: Mechanism of hemodynamic response. Critical Care Medicine 1994;22:A109 24) Schupp E, Kumar A, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: The cardiovascular response to incremental doses of dobutamine in septic shock: Prediction of survival. Critical Care Medicine 1994;22:A109 25) Kumar A, Kosuri R, Kandula P, Lakshminarayanan L, Bunnell, Dee L, Olson J, Uretz E, Parrillo JE: Interleukin-1 but not endotoxin, interferon-, or interleukin-6 depresses myocardial cell contractility in-vitro. Clinical Research 1994;42:168A 26) Kumar A, Kosuri R, Kandula P, Lakshminarayanan L, Dee L, Olson J, Uretz E, Parrillo JE: Human septic serum-induced in-vitro cardiomyocyte depression is caused by the synergistic action of TNF- and IL-1. Clinical Research 1994;42:168A 27) Kumar A, Schupp E, Bunnell E, Uretz E, Calvin J, Ali A, Parrillo JE: Cardiovascular response to dobutamine in septic shock. Clinical and Investigative Medicine 1994;17:B18 #107 28) Kumar A, Dee L, Olson J, Uretz E, Parrillo JE: Human septic serum induced cardiomyocyte depression is caused by the synergistic action of TNF- and IL-1. Clinical and Investigative Medicine 1994;17:B19 #115 29) Kumar A, Kosuri R, Kandula P, Olson J, Dee L, Uretz E, Parrillo JE: Interleukin-1-induced myocardial cell depression is mediated by nitric oxide and cyclic GMP generation. Critical Care Medicine 1995;23:A149 30) Kumar A, Kandula P, Lakshminarayanan L, Dee L, Olson J, Uretz E, Parrillo JE. IL-1 but not endotoxin, IL-2, IL-4, IL-6, IL-8, IL-10, or interferon- depresses myocardial cell contractility in-vitro. Critical Care Medicine 1995;23:A168 31) Kumar A, Kosuri R, Kandula P, Dee L, Olson J, Uretz E, Parrillo JE. Human septic serum induces depression of cardiac myocyte contraction through the synergistic actions of TNF- and IL-1. Critical Care Medicine 1995;23:A262 32) Kumar A, Thota V, Kosuri R, Kandula P, Olson J, Dee L, Uretz E, Parrillo JE: Tumor necrosis factor impairs epinephrine-stimulated cardiomyocyte contractility and cyclic AMP response. Critical Care Medicine 1995;23:A148

42

33) Goldfarb R, Guynn T, Kumar A, Trenholme G, Parrillo JE: Cardiovascular abnormalities of human sepsis modeled in the pig. Crit Care Med 1995;23:A150 34) Sun Y, Kumar A, Hollenberg SM, Porter E, Parrillo JE: Transforming growth factor inhibits tumor necrosis factor-induced depression of cardiac myocyte contractility. Journal of Investigative Medicine (Clinical Research) 1995;43;480A 35) Sun Y, Brar R, Kumar A, Hollenberg SM, Parrillo JE. Effects of nitric oxide synthase (NOS) inhibition on tumor necrosis factor-induced depression of cardiac myocytes in-vitro. J Invest Med 1996;44:447A 36) Brar R, Kumar A, Schaer GL, Hollenberg S, Hursey T, Sun Y, Parrillo JE: Myocardial infarction and reperfusion produces soluble myocardial depressant activity that correlates with infarct size. Crit Care Med 1996;24:A30 37) Kumar A, Brar R, Sun E, Olson J, Parrillo JE: Tumor necrosis factor- (TNF) impairs isoproterenol-stimulated cardiac myocyte contractility and cyclic AMP production via a nitric oxide-independent mechanism. Crit Care Med 1996;24:A95 38) Kumar A, Sun E, Parrillo JE: Endotoxin does not contribute to cardiac myocyte depression produced by TNF, IL-1, or human septic serum. Crit Care Med 1996;24:A95 39) Brar R, Kumar A, Schaer G, Hollenberg S, Hursey T, Sun Y, Parrillo J: Release of soluble myocardial depressant activity by reperfused myocardium. JACC 1996;27:386A. 40) Kumar A, Kosuri R, Dee L, Allen J, Parrillo JE: Divergent effects of epinephrine and amrinone on contractility and cyclic AMP generation of TNF-exposed cardiac myocytes. Crit Care Med 1997;25:A114. 41) Kumar A, Anand A, Krottapalli H, Alahdab K, Wang P, Skorupa G, Hollenberg S, Parrillo JE: Transforming growth factor (TGG)- inhibits TNF and IL-1-induced depression of cardiac myocyte contractility. Critical Care Medicine 1998;26:A39. 42) Kumar A, Alahdab K, Anand A, Krottapalli H, Wang P, Skorupa G, Khadour F, Schulz R, Parrillo JE: Early depression of cardiac myocyte contractility induced by a synergistic combination of TNF and IL-1 is mediated by constitutive nitric oxide (NO) synthetase and cyclic GMP (cGMP). Crit Care Med 1998;26:A34. 43) Kumar A, Kumar A, Parrillo JE: Characterization of intracellular signaling components involved in sepsis. European Cytokine Network 1998;9(3):356 44) Symeonides S, Kumar Anand, Trenholme G, Kumar Aseem, Prasad B, Saleem M, Narang P, Avula S, Aboul-Saoud A, Lingam D, Skorupa G, Matuschek M, Parrillo JE: A

43

new murine model of E. coli peritonitis and septic shock. Program and Abstracts 36th Annual meeting of the Infectious Diseases Society of America 1998 abstract #190 page 111 45) Rozynek M, Parmar M, Paladugu B, Pellekonda V, Malik V, Krottapalli H, Yenigalla Y, Kumar Aseem, Parrillo JE, Kumar Anand. Tumor necrosis factorα (TNFα) impairs catecholamine-stimulated myocyte contractility via both nitric oxide-dependent and independent mechanisms. J Invest Med 1998;46:253A 46) Prasad B, Rozynek M, Zarzycka E, Saleem M, Taiberg L, Kumar Aseem, Symeoneides S, Matuschek M, Skorupa G, Trenholme G, Parrillo JE, Kumar Anand. A new murine model of E. coli peritonitis and septic shock. J Invest Med 1998;46:257A 47) Kumar Aseem, Kumar Anand, Symeonides S, Skorupa G, Paladuga B, Lingam D, Saleem A, Avula A, Sindha K, Aboul-Saoud A, Surapaneni K, Narang P, Parvathala P, Vukonich M, Goldfarb R, Parrillo JE. Characterization of intracellular signalling components involved in sepsis. Crit Care Med 1999;27:A58 48) Kumar Anand, Kumar Aseem, Choudhury E, Saleem M, Avula S, Parvathala P, Aboul-Saoud A, Surapaneni K, Lingam D, Prasad B, Skorupa G, Parrillo JE. Transforming growth factor (TGF)- inhibits human septic serum-induced depression of cardiac myocyte contractility. Crit Care Med 1999;27:A124 49) Symeoneides S, Kumar Aseem, Prasad B, Saleem M, Narang P, Avula S, Aboul-Saoud A, Lingam D, Skorupa G, Matuschek M, Goldfarb R, Trenholme G, Parrillo JE and Kumar Anand. A novel murine model of E. coli peritonitis simulates human septic shock. Crit Care Med 1999;27:A127 50) Kumar Anand, Symeoneides S, Kumar Aseem, Prasad B, Saleem M, Avula S, Makkena R, Battula R, Lingam D, Sindha K, Skorupa G, Matuschek M, Goldfarb R, Trenholme G and Parrillo JE. A novel murine model of E. coli peritonitis simulates human septic shock. Journal of Investigative Medicine 1999;47:197A. 51) Kumar Aseem, Kumar Anand, Vukonich M, Skorupa G, Symoneides S, Prasad B, Lingam D, Saleem A, Avula S, Sindha K, Parvathala P, Makkena R, Battula R and Parrillo JE. Transcription factor activation in myocardial tissue exposed to human septic serum. Journal of Investigative Medicine 1999;47:197A. 52) Kumar Aseem, Kumar Anand, Vukonich M, Skorupa G, Paladugu B, Saleem M, Narang P, Battula R, Sindha K, Lingam D, Parvathala P, Avula S, Aboul-Saoud A, Merchant H, Makkena R, Haery C and Parrillo JE: Characterization of intracellular signalling components involved in sepsis. The Miami 1999 Nature Biotechnology Winter Symposium. Miami nature Biotechnology Short Reports, Volume 10: Advances in Gene Technology; Signal transduction and therapeutic strategies, 1999;10:74

44

53) Kumar Anand, Kumar Aseem, Skorupa G, Vukonich M, Paladugu B, Saleem A, Narang P, Avula S, Parvathala P, Lingam D, Sindha K, Battula R, Makkena R, Haery C and Parrillo, JE. Early human septic serum-induced cardiac myocyte depression is caused by synergistic stimulation of a constitutive nitric oxide synthase by TNF and IL-1. The Miami 1999 Nature Biotechnology Winter Symposium. Miami nature Biotechnology Short Reports, Volume 10: Advances in Gene Technology; Signal transduction and therapeutic strategies, 1999;10:39 54) Haery C, Symeoneides S, Kumar Aseem, Prasad B, Skorupa M, Vukonich M, Goldfarb R, Trenholme G, Parrillo JE, Kumar Anand. A novel murine model of E. coli sepsis. Chest 1999:116;288S. 55) Kumar Aseem, Kumar Anand, Vukonich M, Haery C, Parrillo JE. Characterization of the JAK/STAT pathway during sepsis. Crit Care Med 1999;27:262. 56) Kumar Aseem, Kumar Anand, Parrillo JE. Identification of gene expression patterns during sepsis utilizing DNA gene arrays. Crit Care Med 1999;27:263. 57) Pahwa R, Anel R, Alahdab MT, Alahdab MK, Schupp E, Sun F, Ali A, Parrillo JE, Kumar Anand. Cardiovascular response to dobutamine in septic shock. Crit Care Med 1999;27:384. 58) Anel R, Paladugu B, Makkena R, Haery C, Ganga H, Skorupa G, Vukonich M, Kumar Aseem, Parrillo JE, Kumar Anand. TNF induces a proximal defect of -adrenoreceptor signal transduction in cardiac myocytes. Crit Care Med 1999;27:248. 59) Jindal N, Paladugu B, Haery C, Makkena R, Patel D, Adoni N, Patel V, Vukonich M, Trenholme G, Kumar Aseem, Parrillo JE, Kumar Anand. Antibiotics and fluid resuscitation in a murine model of septic shock. Crit Care Med 1999;27:269. 60) Landgarten M, Paladugu B, Makkena R, Haery C, Patel D, Adoni N, Vukonich M, Skorupa G, Trenholme G, Kumar Aseem, Parrillo JE, Kumar Anand. Timing of steroid administration in septic shock. Crit Care Med 1999;27:265. 61) Anel RL, Schupp E, Marshall S, Parrillo JE, Kumar A. Cardiovascular response to dobutamine infusion in human septic shock. Crit Care Med 2000;28:617. 62) Anel RL, Bunnell G, Habet K, Neumann A, Parrillo JE, Kumar A. Normal saline increases ejection fraction in normal volunteers. Crit Care Med 2000;28:166. 63) Zanotti S, Bunnell G, Parrillo JE, Habet K, Neumann A, Anel R, Toya S, Cutler D, Kumar A: Interleukin-10 administrations blunts the pro-inflammatory cytokine response to endotoxin challenge in healthy volunteers. Crit Care Med 2001;29:55

45

64) Osman J, Paladugu B, Parrillo JE, Taiberg L, Haery C, Kumar Aseem, Kassas E, Kakadia H, Goldfarb R, Kumar Anand: Tranforming growth factor-1 decreases mortality during murine endotoxic shock. Crit Care Med 2001;29:137/S28 65) Osman J, Taiberg L, Paladugu B, Kumar Aseem, Goldfarb R, Parrillo JE, Kumar Anand. Myocardial depression measured with a micro-conductance catheter in a murine model of endotoxic shock. Crit Care Med 2002:30:A70 66) Taiberg L, Osman J, Paladugu B, Kumar Aseem, Goldfarb R, Parrillo JE, Kumar Anand. Transforming growth factor-1 blocks endotoxin-induced myocardial depression in mice. Crit Care Med 2002;30:A55 67) Osman J, Parrillo JE, Kumar A. Improved survival in a murine model of endotoxin-induced shock by transforming growth factor-β1. Clinical and Experimental Pharmacology and Physiology 2002;29:A90. 68) Jilkina O, Kuzio B, Kumar A, Kupriyanov VV. Effects of Profinflammatory cytokines released during sepsis and septic shock on cardiac energetics, mitochondrial K+ transport and oxygenation. Exp Clin Cardiol 2004;9(1):58 69) Roberts D, Kumar A, Sharma S. Time to appropriate antibiotic administration is a critical determinant of outcome in pneumonia-associated septic shock. Chest 2004 2004;126:724S 70) Kumar A, Mensing J, Zelenitsky S, Ariano R, Parrillo JE. Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, A-1296 page 26. 71) Kumar A, Wood K, Gurka D, Feinstein D, Roberts D. Duration of hypotension prior to antimicrobial administration is a critical determinant of outcome in human septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, K-415, page 326. 72) Kumar A, Wood K, Gurka D, Feinstein D, Roberts D. Outcome of septic shock correlates with duration of hypotension prior to source control implementation. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, K1222, page 350. 73) Kumar A, Mensing J, Haery C, Paladugu B, Taiberg L, Osman J, Parrillo JE. Duration of hypotension prior to antibiotic administration is a critical determinant of outcome in a murine model of E. coli septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, A-1861, page 36.

46

74) Ronald J, Suppes R, Gulati H, Halmarson E, Selaman M, Dellinger P, Kramer A, Roberts D, Kumar A. Effect of timing of antimicrobial administration on mortality in septic shock patients. The Toronto Critical Care Medicine Symposium 2004 75) Ronald J, Suppes R, Gulati H, Halmarson E, Selaman M, Dellinger P, Kramer A, Roberts D, Kumar A. Survival from septic shock correlates with duration of hypotension prior to source control implementation. The Toronto Critical Care Medicine Symposium 2004 76) Kumar A, Kazmi M, Roberts D, Wood K, Taiberg L, Feinstein D, Gurka D, Ronald J, Sharma S, Kramer A, Suppes R, Parrillo JE. Duration of shock prior to antimicrobial administration is the critical determinant of survival in human septic shock. Crit Care Med 2004:32 (12 suppl): #41 page 11. 77) Kumar A, Kazmi M, Ronald J, Seleman M, Roberts D, Gurka D, Wood K, Suppes R, Feinstein D, Zanotti S, Parrillo J, Dellinger P. Rapidity of source control implementation following onset of hypotension is a major determinant of survival in human septic shock. Crit Care Med 2004:32(12 suppl): #564 page 160. 78) Kumar A, Kumar A, Paladugu B, Mensing J, Haery C, Symeoneides S, Goldfarb R, Parrillo JE. Duration of hypotension prior to antibiotic therapy is a critical determinant of survival in a murine model of E. coli septic shock. Crit Care Med 2004:32 (12 suppl): #507 page 143. 79) Pakhale S, Roberts D, Light R, Sharma S, Kumar A. A geographically and temporally comprehensive analysis of septic shock: Impact of age, sex and socioeconomic status. The Toronto Critical Care Medicine Symposium 2005. 80) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A. Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. The Toronto Critical Care Medicine Symposium 2005. Can J Anesthesia 2006;53:418-419 81) Nahra R, Mankad A, Zanotti S, Kumar A. Mycobacterium Tuberculosis: An unusual yet highly fatal cause of septic shock. Chest 2005;128:380S 82) Shanaah A, Zanotti S, Parrillo S, Taiberg L, Feinstein D, Suppes R, Roberts D, Kumar A. Impact of body mass index on mortality in patients with septic shock. Critical Care Medicine 2005;33:A164 83) Pakhale S, Roberts D, Light R, Sharma S, Kumar A. A geographically and temporally comprehensive analysis of septic shock: Impact of age, sex and socioeconomic status. Critical Care Medicine 2005;33:A79.

47

84) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Identification and characterization of mediators of sepsis. ACFAS, Montreal, Canada. March 2006. 85) Al-Shirawi N, Arabi Y, Kumar A, Kim C, Li J, Jaswal D, Gonzales C, Serrano R, Delgra S, Al-Shimemeri A, Memish Z. Impact of antibiotic timing outcome of cirrhotic patients admitted to the ICU with septic shock. Proceeding of the American Thoracic Society 2006 Conference. San Diego, CA USA, #A500 86) Tessier M, Tonnos M, Michael P, Brabant D, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of signaling pathways that occur during sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2006. 87) Kung S, Michael P, Tonnos M, Brabant D, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. The role that bacterial RNA plays in mediating myocyte contraction depression. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2006. 88) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Sepsis mediated cellular dysfunction is mediated by DFF 40-induced apoptosis. NOSM Lakehead Research Conference. June 2006. 89) Brabant D, Michael P, Tonnos M, Tessier M, Kung S, Kirwan T, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Human septic sera induces death receptor-mediated apoptosis in human fibroblasts. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 90) Kirwan T, Brabant D, Michael P, Tessier M, Tonnos M, Kung S, Omri A, Ramana CV, Kumar Anand, Parillo JE and Kumar Aseem. Characterization of intracellular signaling components involved in sepsis. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 91) Kung S, Michael P, Tonnos M, Tessier M, Brabant D, Kirwan T, Kekkonen V, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Bacterial RNA and viral RNA-mediated stress-induced apoptosis involves double-stranded RNA Protein Kinase (PKR) pathway. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 92) Tonnos M, Tessier M, Michael P, Brabant D, Kung S, Kirwan T, Omri A, Ramana CV, Kota R, Parissenti AM, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of gene expression profiles that occur during sepsis. Canadian Federation of Biological Sciences, Ottawa, ON, October 2006. 93) Bahador M, Spevetz A, Milcarek B, Parrillo JE, Kumar A. The relationship of presenting body temperature and WBC count of septic shock patients with survival and

48

length of stay in hospital. Crit Care Med 2006;34 (suppl): A103 #377 94) Zarychanski R, Gulati H, Roberts D, Sharma S, Houston DS, Kumar A. Systemically administered heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med 2006;34 (suppl): A110 #398 95) Kirwan T, Michael P, Brabant D, Tonnos M, Kung S, Tessier M, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of transcription factor signaling pathways in sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007 96) Brabant D, Michael P, Tonnos M, Kung S, Kirwan T, Tessier M, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterizing the role that the extrinsic and intrinsic apoptotic pathways play during sepsis. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007. 97) Kung S, Michael P, Tessier M, Brabant M, Kirwan T, Tonnos M, Omri A, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Late stage sepsis gene expression profiling. Northern Research Conference, Northern Ontario School of Medicine and Algoma University, Sault St. Marie, Ontario, Canada. June 2007. 98) Kumar A, Suppes R, Gulati H, Halmarstrom E, Dodek P. The impact of initiation of inadequate antimicrobial therapy on survival in human septic shock. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007 99) Kumar A, Suppes R, Gulati H, Halmarstrom E, Skrobik Y, Ellis P. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007 100) Brabant D, Kirwan T, Michael P, Tonnos M, Kung S, Ramana CV, Omri A, Parrillo HE, Kumar A and Kumar A. Characterization of transcription factor signaling pathways in sepsis. International Society for Interferon and Cytokine Research (ISICR) 2007 101) Brabant D, Kirwan T, Michael P, Tonnos M, Kung S, Ramana CV, Omri A, Parrillo HE, Kumar A and Kumar A. Characterization of sepsis induced apoptotic pathways. International Society for Interferon and Cytokine Research (ISICR) 2007 102) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholecystitis-related septic shock: Impact of rapidity of antimicrobial therapy and source control. Canadian Critical Care Forum 2007

49

103) Siddiqui F, Chateau D, Galbraith J, Kumar A and the CATSS Database Research Group. Early changes in serum creatinine and vasopressors are associated with mortality in septic shock. Canadian Critical Care Forum 2007 104) Siddiqui F, Woodward B, Wang Y, Kumar A and the CATSS Database Study Group. Cumulative Vasopressor Index (CVI) as an assessment of cardiovascular organ dysfunction and indicator of outcome in patients with septic shock. Canadian Critical Care Forum 2007 105) Siddiqui F, Kumar R, Fu W, Chan C, Ren J, Kosick T, Peters C, Sullivan K, Muggaberg S, Kravetsky L, Bohmeier R, Tchokonte R, Khan F, Campbell L, Paulin H, Kumar A and the CATSS Database Research Group. The high mortality of candida septic shock is explained by excessive delays in initiation of antifungal therapy. Canadian Critical Care Forum 2007 106) Siddiqui F, Kumar R, Khan F, Campbell L, Paulin H, Fu W, Chan C, Ren J, Kosick T, Peters C, Sullivan K, Muggaberg S, Kravetsky L, Bohmeier R, Tchokonte R, Kumar A and the CATSS Database Research Group. Candida septic shock mortality is explained by delays in initiation of antifungal therapy. Critical Care Medicine 2007:35 (suppl); A248 # 892 107) McCarthy B, Sullivan K, Muggaberg S, Kravetsky L, Kumar R, Fu W, Chan C, Ren J, Kosick T, Peters C, Bohmeier R, Tchokonte R, Khan F, Campbell L, Paulin H, Kumar A and the CATSS Database Research Group. The impact of initiation of inadequate antimicrobial therapy on survival in human septic shock. Critical Care Medicine 2007:35 (suppl); A146 #532 108) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholangitis-related septic shock: Impact of rapidity of antimicrobial therapy and source control. Critical Care Medicine 2007:35 (suppl); A149 #543 109) McCarthy B, Fu W, Sullivan K, Peters C, Muggaberg S, Kravetsky L, Bohmeier R, Kumar R, Kosick T, Chan C, Ren J, Paulin H, Khan F, Campbell L, Kumar A and the CATSS Database Research Group. Cholecystitis-related septic shock: Impact of rapidity of antimicrobial therapy and source control. Critical Care Medicine 2007:35 (suppl); A152 #551 110) Siddiqui F, Chateau D, Kumar A and the CATSS Database Research Group. Early changes in serum creatinine compared to vasopressors and association with septic shock mortality. Critical Care Medicine 2007:35 (suppl); A177 #637 111) Siddiqui F, Woodward B, Wang Y, Kumar A and the CATSS Database Study Group. Cumulative vasopressor index (CVI) as an assessment of cardiovascular organ

50

dysfunction and indicator of outcome in patients with septic shock. Critical Care Medicine 2007:35 (suppl); A7 #28 112) Low R A, Ahsan AH, Chou H, Bahrainian M, Singh A, Kumar A and the CATSS Database Group. Central-line related septic shock: Early appropriate antimicrobial therapy and rapid catheter removal reduce mortality. 28th International Symposium on Intensive Care and Emergency Medicine. 2008 Brussels, Belgium. 113) Hussein S, Kung S, Bleiblo F, Michael P, Brabant D, Kirwan T, Ramana CV, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of bacterial RNA- induced signal transduction pathways that cause cellular dysfunction. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 114) Kirwan T, Michael P, Brabant D, Bleiblo F, Kung S, Hussein S, DeLongchamp J, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Characterization of the role of STAT, IRF and NF-κB signaling during sepsis. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 115) Kirwan T, Michael P, Brabant D, Bleiblo F, Kung S, Hussein S, DeLongchamp J, Ramana CV, Omri A, Parrillo JE, Kumar Anand and Kumar Aseem. Human septic sera induces apoptosis and DNA Fragmentation Factor 40 activation in human fibroblasts. Northern Health Research Conference, North Bay, Ontario, Canada. May 2008. 116) Manji R, Ahsan MW, Kumar A, CATSS Database Research Group. In septic patients with low cardiac index, initial high or low pulmonary capillary wedge pressure Is not useful to determine ICU outcome. Critical Care Med 2009;37:A239. 117) Manji R, Ahsan MW, Kumar A, CATSS Database Research Group. Patients with septic shock and low cardiac index have inadequate septic treatment and have worse outcomes. Critical Care Med 2009;37:A240. 118) Zarychanski R, Turgeon AF, Hebert PC, Cook DJ, Tinmouth A, Kumar A et al. The use of anticoagulants in severe sepsis and septic shock: A national survey of critical care physicians. Crit Care Med 37[12 (suppl)], A427. 2009 119) Zubert S, Kumar A, Funk D. Reduction in time to effective antimicrobial therapy and survival in human septic shock in community and teaching hospital emergency departments. Canadian Critical Care Forum 2010 120) Muscedere J, Long J, Ofner M, Kumar A, McGeer A , Marshall J, Jouvet P, Cook C, Fowler R for the ICU-Flu Study Investigators. Prevalent and incident bacterial infections among Canadian critically ill patients with Influenza A(H1N1) 2009. Canadian Critical Care Forum 2010

51

121) Jung J, Fowler R, Long J, Zarychanski R, Rodin R, Cook D, Jouvet P, Marshall J, Kumar A on behalf of the ICU-Flu Investigators. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians. Canadian Critical Care Forum 2010 122) Delaney J, Fowler R, Long J, Lamontagne F, Marshall J, Kumar A, Cook D, Hutchison J, Jouvet P on behalf of the ICU-Flu Investigators. Corticosteroids in the treatment of Influenza A 2009 (H1N1)-associated critical illness. Canadian Critical Care Forum 2010 123) Beck V, Kumar A and the CATSS Database Research Group. Does delay in vasopressor administration affect mortality in patients with septic shock? Crit Care Medicine 2011. 124) Muscedere J, Long J, Ofner M, Kumar A, McGeer A, Marshall J, Jouvet P, Cook D, Fowler R for the ICU-Flu Study Investigators. Prevalent and incident positive bloodstream and respiratory cultures among Canadian critically ill patients with influenza A (H1N1) 2009-Preliminary data. Am J Resp Crit Care Med 2011;xxxx :xxxx 125) Kho M, McDonald E, Zytaruk N, Tkaczyk A, Fowler R, Christian M, Kumar A, Burns K, Marshall J, Cook D. Clinical research preparation for the H1N1 pandemic. Am J Resp Crit Care Med 2011;18124 :A104 126) Sharma S, Liu E, Sahai B, Kumar A, Summers R. Quantitation of cytokines and chemokines in the lungs of severely ill 2009 H1N1 patients. Am J Respir Crit Care Med 183;2011:A5230 127) Delaney J, Fowler R, Long J, Lamontagne F, Marshall J, Kumar A, Hutchison J, Jouvet J, On behalf of the ICU-Flu Investigators. Corticosteroids in the treatment of Influenza A 2009 (H1N1) - associated critical illness. Am J Resp Crit Care Med 2011; 17678:B49 128) Gu S, Long J, Menon K, Cook D, McGeer A, Kumar A, Jouvet P, Marshall J, Hutchison J, Fowler RA On behalf of the ICU-Flu Investigators. A Comparison of the First and Second Waves of H1N1-Related Critical Illness in Canada. Am J Resp Crit Care Med 2011;17711:B49. 129) Jung J, Fowler R, Long J, Zarychanski R, Rodin R, Cook D, Jouvet P, Marshall J, Kumar A, On behalf of the ICU-Flu Investigators. 2009-2010 H1N1-related critical illness among aboriginal and non-aboriginal Canadians. Am J Resp Crit Care Med 2011;16731:B49. 130) Kharma N, Gerstein R, Kumar A, Sharma S.. Chest radiographic and CT findings in pandemic influenza A (H1N1) virus infection. Am J Respir Crit Care Med 183;2011:A4920

52

131) Rimmer E, Kumar A, Houston D, Doucette S, Zarychanski R. Activated protein C and septic shock: A propensity-matched cohort study. International Society of Thrombosis and Hemostasis 2011. 132) Ariano RE, Zelenitsky SA, Kumar A, Baxter M, Adam H, Karlowsky JA, Hoban DJ, Canadian Antimicrobial Resistance Alliance (CARA), Zhanel GG. Antimicrobial resistance in 4105 pathogens from Canadian hospital intensive care units (ICU): CANWARD database 2007-2010. ICAAC 2011. 133) Alkurdi N, Kumar A, Ariano R, Zelenitsky S, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Investigating ceftobiprole (Cef) alone and in combination with daptomycin (Dap), linezolid (Lin) and vancomycin (Van) against methicillin-resistant Staphylococcus aureus (MRSA) in an in vitro infection model. ICAAC 2011. 134) Sood MM, Rigatto C, Shafer LA, Bueti J, Komenda P, Kumar A for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Reversible AKI is associated with improved survival compared to persistent or no AKI in septic shock. American Society for Nephrology 2012 135) Mandelzweig K, Sood MM, Rigatto C, Komenda K, Bueti J, Kumar A for the Cooperative Antimicrobial Therapy in Septic Shock (CATSS) Database Research Group. Site of infection impacts presence and severity of septic AKI. American Society for Nephrology 2012 136) Rimmer E, Kumar A, Houston D, Doucette S, Zarychanski R. Activated protein C and septic shock: A propensity-matched cohort study. Crit Care Med 2011;39 (suppl): #39 137) Rimmer E, Kumar A, Turgeon A, Makar B, Houston D, Zarychanski R. Clinical use of activated protein C inn septic shock: Results from a multinational cohort. Crit Care Med 2011;39 (suppl): #392 138) Makar B, Weldon E, Webb A, Peters H, Turgeon A, Houston D, Rimmer E, Kumar A, Zarychanski R. Frozen plasma to red blood cell ratio and mortality in patients requiring massive transfusion. Crit Care Med 2011;39 (suppl): #282 139) Kethireddy S, Funk D, Kumar A. Septic shock from Mycobacterium tuberculosis. Crit Care Med 2011;39 (suppl): #532 140) Funk D, Kethireddy S, Doucette S, Kumar A. Use of low dose (stress) corticosteroids in patients with septic shock. Crit Care Med 2011;39 (suppl): #289.

53

141) Dara SI, Arabi YM, Tamim HM, Rishu AH, Kumar A. Pneumonia as a cause of septic shock is not associated with worse outcomes compared to non-pneumonia causes. ATS 2012 142) Al-Dorzi HM, Tamim H, Bouchama A, Kumar A, Arabi YM. Presentation and outcome of diabetic patients admitted with septic shock. ATS 2012 143) Dara SI, Arabi YM, Tamim HM, Rishu AH, Kumar A. Female Gender and Outcomes Among Patients Admitted With Septic Shock. ATS 2012 144) Kumar A and the ROSII Investigators. Viral Clearance with Standard or Triple Dose Oseltamivir Therapy in Critically Ill Patients with Pandemic (H1N1) 2009 Influenza. ICAAC 2013 145) Kethireddy S, Light RB, Mirzanejad Y, Maki D, Simon D, Kumar A, Parrillo JE, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Characteristics And Outcomes Of Patients With Culture Negative Septic Shock Compared To Patients With Culture Positive Septic Shock: A Retrospective Cohort Study. International Sepsis Forum 2013 146) Bednarczyk J, Kethireddy S, White CW, Freed DH, Bell D, Kumar A, Light B. Extracorporeal Membrane Oxygenation facilitates Survival in Blastomycosis related Acute Respiratory Distress Syndrome. Canadian Critical Care Forum 2013. 147) Rimmer E, Houston B, Kumar A, Abou-Setta AM, Friesen C3, Turgeon AF, Cook DJ, Houston DS, Zarychanski R. The Efficacy and Safety of Therapeutic Apheresis in Patients with Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Canadian Critical Care Forum 2013 148) Mooney O, Bell D, Turgeon A, Kumar A, Houston D, Rimmer E, Zarychanski R. Nucleated Red Blood Cells as an Independent Predictor of ICU Mortality and Recidivism. Canadian Critical Care Forum 2013. 149) Craig J, Daneman N, Rishu A, Xiong W, Bagshaw SM, Dodek PE, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin C, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler R for the BALANCE Study Group. Adjudication of Duration Of Adequate Antimicrobial Treatment In Critical Care. Canadian Critical Care Forum 2013 150) Rishu A, Daneman N, Xiong W, Bagshaw SM, Dodek PE, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin C, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler R for the BALANCE Study Group.. Description Of Duration Of Treatment For Bloodstream Infection In Critically Ill Patients: A Multi-Centre Observational Study. Canadian Critical Care Forum 2013

54

151) Daneman N , Rishu A, Xiong W, Bagshaw SM, Dodek PE, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin C, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler R for the BALANCE Study Group. Patient And Pathogen Predictors Of Antibiotic Treatment Duration For Bloodstream Infection In Critically Ill Patients. Canadian Critical Care Forum 2013 152) Rimmer E, Houston B, Kumar A, Abou-Setta AM, Friesen C3, Turgeon AF, Cook DJ, Houston DS, Zarychanski R. The Efficacy and Safety of Therapeutic Apheresis in Patients with Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. American Society of Hematology 2013. 153) Daneman N, Rishu A, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Patient And Pathogen Predictors Of Antibiotic Treatment Duration For Bloodstream Infection In Critically Ill Patients. B48-Sepsis and Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 154) Craig J, Daneman N, Rishu A, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Measuring The Duration Of Adequate Antimicrobial Treatment For Blood Stream Infections In Critically Ill Patients. B48-Sepsis and Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 155) Rishu A, Daneman N, Xiong W, Bagshaw SM, Dodek PM, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, McIntyre LA, Martin C, Muscedere J, Reynolds S, Stelfox HT, Fowler R: Description Of Duration Of Treatment For Bloodstream Infection In Critically Ill Patients: A Multi-Centre Observational Study. B48-Sepsis and Pneumonia: Treatment And Outcomes, American Thoracic Society Annual Symposium, May 19, 2014, San Diego, USA. 156) Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A. Houston DS ; Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hebert PC, Cook DJ, Fergusson DA. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis Belgium 2015

55

invited lectures (extra-mural) 1) Mechanisms of myocardial cell depression in human septic shock. Award Lecture. Society for Critical Care Medicine Annual Scientific Session (New York, NY) April 1993 2) SIRS (systemic inflammatory response syndrome), sepsis and septic shock. American Academy of Neurology Annual Scientific Symposium (Washington, DC) May 1994 3) Sepsis and septic shock. University of Wisconsin 13th Annual Critical Care Symposium (Madison, WI) September 1995 4) The nature of myocardial dysfunction in human septic shock. Merck J. Wayne Ebrite Infectious Diseases Research Conference. (West Point, PA) November 1995 5) Pharmacology of vasoactive drugs. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1997 6) Central nervous system infections. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1997 7) Pathogenesis and therapy of sepsis and septic shock. University of Wisconsin 14th Annual Critical Care Symposium (Madison, WI) October 1997 8) Infections in the immunosuppressed. Society of Critical Care Medicine Review Course (San Antonio, TX) February 1998 9) Poster Moderator: Sepsis. Society of Critical Care Medicine Annual Scientific Symposium (San Antonio, TX) February 1998 10) Ethics and the Law: Withdrawal of Life Support in Non-Brain Dead Critically Ill Patients. Holy Cross Hospital Ethics Symposium, (Chicago, IL) April 1998 11) Pharmacology of vasoactive drugs. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1998 12) Central nervous system infections. Society of Critical Care Medicine Board Review Course (Chicago, IL) August 1998 13) Life-threatening infections in the immunosuppressed. Critical Care Medicine Grand Rounds. Los Angeles County Hospital (Los Angeles, CA) July 1998 14) Role of cytokines and nitric oxide in septic myocardial dysfunction. Critical Care Medicine Grand Rounds. University of Wisconsin at Madison (Madison, WI) September 1998

56

15) Antimicrobials in the ICU: Beyond Bugs and Drugs. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 1999 16) Nosocomial and ventilator-associated pneumonia. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 1999 17) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (San Francisco, CA) February 1999 18) On the rational use of antibiotics in the ICU. University of Wisconsin 16th Annual Critical Care Symposium (Madison, WI) October 1999 19) Nosocomial and ventilator-associated pneumonia. University of Wisconsin 16th Annual Critical Care Symposium (Madison, WI) October 1999 20) Septic Myocardial Depression: From bedside to bench and back. NIH Institute on Aging, Cardiovascular Research Labs. Invited Lecture (Baltimore, MD) November 1999 21) Poster Moderator: Cytokines and Sepsis. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2000 22) Septic Shock: Old Precepts, New Concepts. Lutheran General Hospital, Grand Rounds (Chicago, IL) September 2000 23) Fungal Infections and Resistance. Society of Critical Care Medicine Refresher Course (San Francisco, CA) February 2001 24) Poster Moderator: Sepsis Models. Society of Critical Care Medicine Annual Scientific Symposium (San Francisco, CA) February 2001 25) Septic Myocardial Depression. From Bench to Bedside. University of Wisconsin, Critical Care Grand Grounds (Madison, WI) March 2001 26) Septic Myocardial Depression. From Bench to Bedside. University of Calgary, Critical Care Research Rounds (Calgary, Alberta) April 2001 27) Optimization of Antibiotic Use in the ICU. University of Calgary, Critical Care Grand Rounds (Calgary, Alberta) April 2001 28) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care and the Team Approach (Boston, MA) April 28, 2001 29) National Initiative on Sepsis Lectures: Definitions, Epidemiology, Antibiotic Issues and Case Studies (Los Angeles, CA) May 19, 2001

57

30) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Pathways/Guidelines (Chicago, IL) June 19, 2001 31) Septic Shock: Old Precepts, New Concepts. University of Illinois. Continuing Medical Education Lecture (Chicago, IL) July 10, 2001 32) Septic Shock: Old Precepts, New Concepts. St. Mary’s Hospital. Grand Rounds (Hobart, IN) August 8, 2001 33) Septic Shock: Old Precepts, New Concepts. University of Manitoba. Continuing Medical Education Lecture (Winnipeg, Manitoba) August 18, 2001 34) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care and the Team Approach (Laguana Nigel, CA) August 18, 2001 35) Septic Shock: Old Precepts, New Concepts. St. Joseph’s Hospital. Grand Rounds (Chicago, IL) August 29, 2001 36) Septic Shock: Old Precepts, New Concepts. St. Joseph Exempla Hospital. Grand Rounds (Denver, CO) September 7, 2001 37) Septic Shock: Old Precepts, New Concepts. Holy Cross Hospital. Grand Rounds (Chicago, IL) Oct 3, 2001 38) Septic Shock: Old Precepts, New Concepts. St. James Hospital. Grand Rounds (Chicago, IL) Oct 11, 2001 39) Septic Shock: Old Precepts, New Concepts. University of Wisconsin, Milwaukee. Continuing Medical Education Lecture (Milwaukee, WI) Oct 11, 2001 40) National Initiative on Sepsis Regional Lecture: Sepsis and Septic Shock (Chicago, IL) November 1, 2001 41) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Case Studies (Philadelphia, PA) November 3, 2001 42) National Initiative on Sepsis Regional Lecture: Sepsis and Septic Shock (Columbus, OH) November 13, 2001 43) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Critical Care Regional Conference (Pittsburgh, PA) November 17, 2001 44) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Concordia Hospital Grand Rounds (Winnipeg, Manitoba) November 20, 2001

58

45) Septic Shock: New Concepts in Pathophysiology. University of Wisconsin 17th Annual Critical Care Symposium (Madison, WI) November 29, 2001 46) Sepsis and Septic Shock: Cases Studies. University of Wisconsin 17th Annual Critical Care Symposium (Madison, WI) November 30, 2001 47) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, Pathways/Guidelines and Case Studies (San Diego, CA) December 8, 2001 48) National Initiative on Sepsis Lectures: Antibiotic Issues, Supportive Care, the Team Approach and Pathways/Guidelines (St. Louis, MO) December 15, 2001 49) Septic Shock: Old Precepts, New Concepts. City-wide Critical Care Lecture (Winnipeg, Manitoba) January 16, 2001 50) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (San Diego, CA) January 2002 51) Septic Shock: Old Precepts, New Concepts. St. Catherine’s Hospital. Grand Rounds (East Chicago, IL) February 7, 2002 52) The Spectrum of Sepsis: Case Studies. St. Francis Medical Center. Continuing Medical Education Lecture. (Pittsburgh, PA) February 12, 2002 53) Septic Shock: Old Precepts, New Concepts. St. Francis Medical Center, Grand Rounds (Pittsburgh, PA) February 13, 2002 54) Septic Myocardial Depression: From Bedside to Bench and Back. National Research Council, Institute for Biodiagnostics. Invited Research Lecture (Winnipeg, MB) February 15, 2002 55) The Spectrum of Sepsis: Case Studies. Grace General Hospital. Emergency Department Grand Rounds. (Winnipeg, MB) March 12, 2002 56) Septic Shock: Current Management Strategies. St. Luke’s Medical Center. Continuing Medical Education (Duluth, MN) April 9, 2002 57) Septic Shock: Old Precepts, New Concepts. Cambridge Hospital, Grand Rounds (Cambridge, MN) April 10, 2002 58) Antibiotics in Sepsis and Septic Shock. University of North Dakota Medical Center, Grand Rounds (Grand Forks, ND) April 11, 2002 59) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. Critical

59

Care Regional Conference (New York, NY) April 27, 2002 60) Septic Shock: Old Precepts, New Concepts. Hospital HIMA, Grand Rounds (Caguas, Puerto Rico) May 21, 2002 61) Antibiotics in Sepsis and Septic Shock. Hospital La Concepcion, Grand Rounds (San German, Puerto Rico) May 22, 2002 62) Septic Shock: Old Precepts, New Concepts. Hospital San Cristobal Grand Rounds (Coto Laurel, Puerto Rico) May 23, 2002 63) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (Miami, FL) June 8, 2002 64) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (San Antonio, TX) June 22, 2002 65) National Initiative on Sepsis Lectures: Infectious Diseases Issues, Hemodynamic Support, Bioterrorism and Ethical Considerations (Gainesville, FL) June 29, 2002 66) Coagulation Abnormalities in Sepsis and Septic Shock. Biannual Conference on Hemostasis and Coagulation. (Madison, WI) November 11-12, 2002. 67) Convener, Sepsis Forum. Rocky Mountain Critical Care Conference. (Silver Star Mountain Resort, BC) February 20-22, 2003 68) Management of Life-Threatening Fungal Infections in the ICU. City Wide Critical Care Rounds. University of Manitoba (Winnipeg, MB) May 29, 2003 69) Immediate Management Issues in Sepsis and Septic Shock. Canadian Association of Emergency Physicians Annual Meeting, (Winnipeg, MB) June 7, 2003 70) Septic Shock: Old Precepts, New Concepts. Critical Care Grand Rounds. Brandon General Hospital (Brandon, MB) June 17, 2003 71) Shock: A Graphical Analysis based on Venous Return. Critical Care Rounds. Health Sciences Centre (Winnipeg, MB) November 14, 2004 72) Septic Shock: The Sepsis Sixpack, An Overview of Therapy of Sepsis and Septic Shock. Critical Care Rounds. (Winnipeg, Manitoba) January 12, 2004 73) Septic Shock: Emerging Considerations in Early Management. Medical Grand Rounds. Health Sciences Centre and St. Boniface Hospital, University of Manitoba. (Winnipeg, MB). January 28, 2004

60

74) Lack of Utility of PAC-Derived PWP and CVP to Predict Ventricular Volumes and Stroke Volume Response in Normal Humans. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 20, 2004 75) Poster Moderator: Clinical Science: Sepsis/Infection. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2004 76) Poster Moderator: Cardiovascular Disease. Society of Critical Care Medicine Annual Scientific Symposium (Orlando, FL) February 2004 77) An Update on Sepsis and Septic Shock. Anesthesia Grand Rounds. University Hospital, University of Cincinnati (Cincinnati, OH) June 25, 2004. 78) Sepsis and Septic Shock: Old Precepts, New Concepts. SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 79) Life Threatening Pneumonia. SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 80) Optimization of Antimicrobial Therapy (Tutorial Review). SCCM Multidisciplinary Review Course (Chicago, IL) August 2004 81) Sepsis and Septic Shock: An update. Harper Hospital/Wayne State University Critical Care Grand Rounds (Detroit, MI) November 2, 2004 82) On the Optimal Use of Antimicrobials in the ICU: Beyond Bugs and Drugs. City-wide Critical Care Rounds (Regina, SK) November 30, 2004 83) Sepsis and Septic Shock: Old Precepts, New Concepts. City-wide Critical Care Conference (Saskatoon, SK) December 1, 2004 84) Sepsis and Septic Shock: Diagnosis and Management. E-test Application Laboratory, AbBiodisk Inc. MIC and PK/PD for Critical Care: Challenges and Solutions. (Stockholm Sweden) November 2, 2004 85) Optimal Use of Antimicrobial Agents in the ICU. Beyond Bugs and Drugs. E-test Application Laboratory, AbBiodisk Inc. MIC and PK/PD for Critical Care: Challenges and Solutions. (Stockholm, Sweden) November 2, 2004 86) Poster Moderator: Cardiovascular Physiology. Society of Critical Care Medicine Annual Scientific Symposium (Phoenix, AZ) January 2005 87) Cardiovascular Dysfunction in Sepsis and Septic Shock: From Bench to Bedside and Back. 1st International Critical Care Medicine Symposium. March 6-10, 2004, National Guard Health Affairs, Riyadh, Saudi Arabia.

61

88) Central Nervous System Infections. 1st International Critical Care Medicine Symposium. March 6-10, 2004, National Guard Health Affairs, Riyadh, Saudi Arabia. 89) Optimization of Antibiotics in the Critically Ill. Beyond bugs and drugs. 1st International Critical Care Medicine Symposium. March 6-10, 2004, National Guard Health Affairs, Riyadh, Saudi Arabia. 90) Fungal Infections in the ICU: Focus on Candida. (Winnipeg, MB) March 15, 2005. 91) Septic Myocardial Depression: From Bench to Bedside and Back. City-Wide Pulmonary Research Conference (Winnipeg, MB), May 4, 2005 92) Septic Myocardial Depression: From Bench to Bedside and Back. Department of Pharmacology Research Conference, University of Manitoba (Winnipeg, MB), May 6, 2005. 93) Optimization of Antimicrobial Therapy in Life-Threatening Infection in the ER. City-wide Emergency Medicine Conference (Winnipeg, MB) May 11, 2005. 94) Life threatening fungal infections in the ICU: Focus on Candida. Merck Canada Annual Sales Meeting, Four Seasons Hotel (Toronto, ON) June 23, 2005 95) Life threatening fungal infections in the ICU: Focus on Candida. Grand Rounds, St. Joseph’s Hospital (Toronto, ON) June 28, 2005 96) Life threatening fungal infections in the ICU: Focus on Candida. Grand Rounds, Lakeridge Community Hospital (Oshawa, ON) June 29, 2005 97) Life threatening fungal infections in the ICU: Focus on Candida. Critical Care Medicine Grand Rounds, Toronto General Hospital (Toronto, ON) June 29, 2005 98) Life threatening fungal infections in the ICU: Focus on Candida. Infectious Diseases Grand Rounds, Toronto General Hospital (Toronto, ON) June 29, 2005 99) Life Threatening Pneumonia. SCCM Multidisciplinary Review Course (Chicago, IL) August 2005 100) Optimization of Antimicrobial Therapy (Tutorial Review). SCCM Multidisciplinary Review Course (Chicago, IL) August 2005 101) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Sepsis Database: The Good, Bad and the Ugly. University of Manitoba Department of Medicine Grand Rounds, Health Sciences Centre (Winnipeg, Manitoba), September 27, 2005 102) Molecular biology of septic shock. Critical Care Fellows Lecture. Health Sciences

62

Centre (Winnipeg, MB) September 28, 2005 103) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Grand Rounds, St. Boniface General Hospital (Winnipeg Manitoba), October 20, 2005 104) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Sepsis Database: The Good, Bad and the Ugly. Bristol Myers Squibb Advisory Meeting (Toronto, Ontario), October 25, 2005 105) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Infectious Diseases/Medical Microbiology Fellows Lecture, University of Manitoba, Health Sciences Centre (Winnipeg Manitoba), November 23, 2005 106) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: An ER Perspective. City-wide ER Grand Rounds. St. Boniface Research Centre (Winnipeg, MB) January 26, 2006 107) Epidemiology of Septic Shock in Manitoba and Canada: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database. University of Manitoba, Department of Community Heath Sciences (Winnipeg, MB) February 17, 2006 108) Septic Shock: Lessons from the Co-operative Antimicrobial Therapy of Septic Shock Database: The Good, Bad and the Ugly. Canadian Critical Care Conference (Whistler BC) Feb 23, 2006 109) Septic Shock: The importance of timing considerations in antimicrobial therapy. Lilly Critical Care Global Medical Conference (in conjunction with the 26th International Symposium on Intensive Care and Emergency Medicine)(Brussels Belgium) March 20, 2006. 110) CSI: Winnipeg. Current investigations in sepsis and septic shock. Annual Critical Eye Nursing Conference, University of Manitoba (Winnipeg, Manitoba) April 10, 2006 111) Pathophysiology and Management of Septic Shock: A Renal Perspective. Canadian Society of Nephrology Annual Meeting 2006 (Quebec City, QC) May 26, 2006 112) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Wyeth Advisory Board Meeting (Toronto, ON) October 15, 2006 113) Septic Shock: Optimizing outcome by optimizing antimicrobial therapy. University of California, Bakersfield Grand Rounds, Kern Medical Centre (Bakersfield, CA). October 19, 2006

63

114) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Toronto Critical Care Medicine Symposium (Toronto, ON) October 27, 2006 115) Antimicrobial therapy of sepsis and septic shock. International Nosocomial Infection Symposium (Winnipeg, MB) Nov 30, 2006. 116) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. St. Agnes Hospital Critical Care Grand Rounds (Baltimore, Maryland) December 13, 2006 117) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Cooper University Hospital Critical Care Grand Rounds (Camden, NJ) December 14, 2006 118) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Association of Medical Microbiology and Infectious Diseases Canada and Canadian Association for Clinical Microbiology and Infectious Diseases Annual Conference (Halifax, NS) March 15, 2007 119) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Grand Rounds, Queen Elizabeth Medical Center, Dalhousie Medical School (Halifax, NX) March 16, 2007 120) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 4, 2007. 121) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 5, 2007. 122) Antimicrobial and supportive therapy of sepsis and septic shock. Winnipeg Regional Health Authority ER Triage Nurse Educational Meetings (Winnipeg, MB) April 11, 2007. 123) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Grand Rounds, Victoria Hospital, University of London, Faculty of Medicine (London, ON) April 25, 2007 124) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University Health Network CME Rounds, University of Toronto (Toronto, ON) April 25, 2007

64

125) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical/Surgical Grand Rounds, Grand River/Kitchener-Waterloo Hospital (London, ON) April 26, 2007 126) Septic Shock: Optimizing Outcomes. Critical Care Medicine City-wide Grand Rounds, Victoria Hospital, University of London, Faculty of Medicine (London, ON) April 27, 2007 127) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical/Surgical Grand Rounds, Nanaimo Regional General Hospital (Nanaimo, BC) May 1, 2007 128) Septic Shock: Optimizing Outcomes. Royal Jubilee/Victoria General Hospitals Combined CME Rounds, University of Victoria, Faculty of Medicine (Victoria, BC) May 1, 2007 129) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Royal Columbian Hospital CME Lecture (New Westminster, BC) May 2, 2007 130) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Respiratory/Critical Care Medicine Rounds, Surrey Memorial Hospital (Surrey, BC) May 3, 2007 131) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Vancouver General Hospital/St. Paul’s Hospital CME Lecture (Vancouver, BC) May 3, 2007 132) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Regina Regional Health Authority CME lecture (Regina, SK) June 4, 2007 133) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, University Hospital (Edmonton, AB) June 5, 2007 134) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, Foothills Hospital, University of Calgary (Calgary, AB) June 6, 2007 135) Sepsis and Septic Shock. Optimizing Outcomes. Grand Rounds, Southlake Hospital (Newmarket, ON) June 25, 2007 136) Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Grand Rounds, Humber River Regional Hospital (Weston,

65

ON) June 25, 2007 137) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Medicine Rounds, Hamilton General Hospital, McMaster University (Hamilton, ON) June 25, 2007 138) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Rounds, Sunnybrook Hospital, University of Toronto (Toronto, ON) June 26, 2007 139) Sepsis and Septic Shock. Optimizing Outcomes. Tri-hospital Critical Care CME lecture, Sunnybrook, North York General, Scarborough General Hospitals (Toronto, ON) June 26, 2007 140) Sepsis and Septic Shock. Optimizing Outcomes. Critical Care Medicine Rounds, Windsor Regional Hospital and Hotel Dieu Grace Hospital (Windsor, ON) June 27, 2007 141) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Grand Rounds. University of Wisconsin Hospital and Clinics (Madison, WI) Sept 11, 2007. 142) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Symposium Lecture. Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL) Sept 17, 2007 143) Diagnosis and Management of Septic Shock. Critical Care Grand Rounds, Rush University and Medical Center (Chicago, IL) Sept 18, 2007 144) Management of Septic Shock. ICU Grand Rounds. St. Joseph’s Hospital and the Sudbury Regional Health Authority (Sudbury, ON) Sept 24, 2007 145) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Sudbury Regional Health Authority CME lecture (Sudbury ON) Sept 24, 2007 146) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City-wide Pharmacy Grand Rounds, Princess Margaret Hospital (Toronto, ON) Sept 25, 2007 147) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City-wide Critical Care Rounds. St. Michael’s Hospital (Toronto, ON) Sept 25, 2007 148) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgery Grand Rounds. McMaster University

66

Medical Center (Hamilton, ON) Sept 26, 2007 149) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ER Grand Rounds. St. Joseph’s Hospital (Hamilton, ON) Sept 26, 2007 150) Management of Septic Shock. St. Catherines Regional Health Authority ER Grand Rounds (St. Catherines, ON) Sept 26, 2007 151) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgery Grand Rounds. Grand River Hospital (Kitchener, ON) Sept 27, 2007 152) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds. Victoria Hospital, London Health Sciences Centre. (London, ON) Sept 27, 2007 153) Management of Septic Shock. Pharmacy/ID Conjoint Rounds. London Health Sciences Centre (London, ON) Sept 27, 2007. 154) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds. St. Paul’s Hospital (Vancouver, BC) Oct 11, 2007 155) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. IDology Club. Ottawa General and Ottawa Civic Hospitals. (Ottawa, ON) Oct 15, 2007 156) Optimization of Antimicrobial Therapy in Septic Shock: Speed is Life. Critical Care Rounds. Pharmacy Grand Rounds. (Ottawa, ON) Oct 16, 2007 157) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. 16th Critical Care Medicine Conference, University of Wisconsin (Madison, WI) Oct 23, 2007 158) Cardiovascular Dysfunction in Septic Shock: From Bench to Bedside and Back. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2007 159) Managing Infections in the Immuno-suppressed Patient. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2007 160) Managing Fungal Sepsis and Septic Shock. Canadian Critical Care Forum (Toronto, ON) Nov 1, 2007 161) Optimizing Antimicrobial Management of Septic Shock: Speed is Life.

67

Canadian Critical Care Forum (Toronto, ON) Nov 1, 2007 162) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ICU and ID/Micro Interhospital Rounds. Pierre Boucher Hospital (Monteregie, QC) Nov 14, 2007. 163) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. McGill University Interdepartmental Rounds, Jewish General Hospital (Montreal, QC) Nov 14, 2007 164) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Montreal General Hospital CME Lecture (Montreal, QC) Nov 14, 2007 165) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. CHUM ICU/ID/Microbiology Interhospital Video-Conference, Notre Dame Hospital (Montreal, QC) Nov 15, 2007 166) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Medical Grand Rounds, Maisonneuve-Rosemont Hospital (Montreal, QC) Nov 15, 2007 167) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Quebec City Inter-hospital CME Lecture (Quebec City, QC) Nov 15, 2007. 168) Optimzing Outcomes in Septic Shock: Speed is Life. University of Massachusetts Medical Center Medical Grand Rounds (Boston, MA) Nov 29, 2007. 169) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Apollo Hospital CME Lecture (New Delhi, Uttar Pradesh, India) Dec 5, 2007. 170) Principles of Treating Infectious Diseases in Critical Care. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007 171) Life-threatening Infections in the Immunosuppressed. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007 172) Shock and Basic Hemodynamic Monitoring. Multiprofessional Board Review Course (Course Director, Anand Kumar), Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 6, 2007

68

173) Optimizing Antimicrobial Management of Sepsis and Septic Shock. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 8, 2007 174) Management of Fungal Sepsis and Septic Shock: Emerging Concepts in Diagnosis and Management. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 8, 2007 175) Utility of PA Catheters and CVP in Critically Ill. Asia Pacific Conference on Critical Care (New Delhi, Uttar Pradesh, India) Dec 9, 2007 176) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Max Super-Specialty Hospital Grand Rounds (New Delhi, Uttar Pradesh, India) Dec 5, 2007. 177) Optimizing Outcome in Septic Shock. Multispecialty Grand Rounds. Altru Medical Center, University of North Dakota (Grand Forks, ND) Jan 16, 2008 178) Antimicrobial Use in the ICU. Medical Microbiology Rounds, University of Manitoba (Winnipeg, MB) Jan 21, 2008 179) Antimicrobial Use in Septic Shock. Medical Microbiology Rounds, University of Manitoba (Winnipeg, MB) Jan 28, 2008 180) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Interdisciplinary ICU/Microbiology/ID Rounds, Royal Glamorgan Hospital (Cardiff, Wales, Great Britain) Feb 25, 2008 181) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Interdisciplinary ICU/Microbiology/ID Rounds, Southampton University Hospital (Southampton, England) Feb 26, 2008 182) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. The London Intensive Care Group City-Wide Rounds, St. Thomas Hospital (London, England) Feb 26, 2008 183) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. ICU/Microbiology/ID Rounds, Birmingham Heartlands Hospital (Birmingham, England) Feb 27, 2008 184) Optimizing Antimicrobial Management of Sepsis and Septic Shock. City-wide ITS/ICU Conference, Birmingham Heartland Hospital (Birmingham, England) Feb 27, 2008 185) Interactive Pneumonia Case History: Focus on Pathogen and Antibiotic Treatment. 1st Intensivists Forum, Hilton Vienna Hotel (Vienna, Austria) Feb 28,

69

2008 186) Saving Lives with Early Antimicrobial Intervention: Speed is Life. 1st Intensivists Forum, Hilton Vienna Hotel (Vienna, Austria) Feb 29, 2008 187) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. 3º Simpósio de Infecção e Sépsis 2008, Sheraton Hotel (Porto, Portugal) April 3, 2008 188) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 2. 3º Simpósio de Infecção e Sépsis 2008, Sheraton Hotel (Porto, Portugal) April 3, 2008 189) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Medical Grand Rounds, Toronto East General Hospital (Toronto, ON) April 16, 2008 190) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Grand Rounds, William Osler Medical Center (Toronto, ON) April 16, 2008 191) Optimizing Outcome in Septic Shock: Lessons from the CATSS database, Speed is Life: Part 1. Critical Care Rounds, Southlake Hospital (Richmond, ON) April 16, 2008 192) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Queens University Hospital (Kingston, ON) April 17, 2008 193) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Gold Coast Hospital (Brisbane, Australia) April 28, 2008 194) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Royal Brisbane and Women’s Hospital (Brisbane, Australia) April 28, 2008 195) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal Melbourne Hospital (Melbourne, Australia) April 29, 2008 196) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Infectious Diseases Rounds, Monash Medical Centre (Melbourne, Australia) April 29, 2008

70

197) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Critical Care Rounds, Peter MacCallum Cancer Institute (Melbourne, Australia) April 30, 2008 198) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal Adelaide Hospital (Adelaide, Australia) April 30, 2008 199) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Royal North Shore Hospital (Sydney, Australia) April 30, 2008 200) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Combined Critical Care and Infectious Diseases Rounds, Westmead Hospital (Sydney, Australia) April 30, 2008 201) A Novel Paradigm of the Pathogenesis of Septic Shock: Predictions and Implications for Management. Special Consulting Lecture. Astra-Zeneca Corporate and Research Center (Wilmington, DE) May 14, 2008 202) Optimizing Outcomes in Fungal Sepsis and Septic Shock. Centre hospitalier de l’Université de Montréal (CHUM) ICU Critical Care Conference (Montreal, QC) June 5, 2008 203) Optimizing Outcomes in Fungal Sepsis and Septic Shock. Medical-Surgical Grand Rounds, Hospital Maissoneuve-Rosemont (Montreal, QC) June 5, 2008 204) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Continuing Education Conference (Montreal, QC) June 5, 2008 205) ICU Management of Gram Positive Septicemia . 4th International Symposium on Resistant Gram-Positive Infections. State University of New York (Buffalo, NY) July 10, 2008 206) Infections in AIDS, Transplant Patients and Other Immunocompromised Hosts. Society of Critical Care Medicine Multiprofessional Critical Care Review Course. (Chicago, IL) August 7, 2008 207) Multi-resistant Infections. Society of Critical Care Medicine Multiprofessional Critical Care Review Course. (Chicago, IL) August 7, 2008 208) Speed is Life: Comparison of Antimicrobial and Non-antimicrobial Therapies Impact on Outcome of Septic Shock. Combined Medical Grand Rounds. St. Luke’s Hospital, University of Wisconsin Milwaukee. (Milwaukee, WI) September 4, 2008

71

209) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Surgical Grand Rounds, Vancouver General Hospital (Vancouver, BC) September 17, 2008 209) Speed is Life: Comparison of Antimicrobial and Non-antimicrobial Therapies Impact on Outcome of Septic Shock. Medical Grand Rounds, St. Paul’s Hospital (Vancouver, BC) September 17, 2008 210) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. City Wide ID Continuing Education Lecture (Vancouver, BC) September 17, 2008 211) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Speed is Life. 6th International Conference on Intensive Care (Quito, Ecuador) Sept 25, 2008 212) Myocardial Depression in Sepsis and Septic Shock. 6th International Conference on Intensive Care (Quito, Ecuador) Sept 25, 2008 213) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Intensifying Therapy. 6th International Conference on Intensive Care (Quito, Ecuador) Sept 25, 2008 214) Debate: Unilateral With-holding and Withdrawing: Can it ever be done? An intensivist’s perspective. The Grey Matter Symposium in conjunction with Canadian Critical Care Forum Annual Meeting 2008. (Toronto, Canada) Nov 10, 2008 215) Why Delays of Antimicrobials Matter in Septic Shock. Canadian Critical Care Forum Annual Meeting 2008. (Toronto, Canada) Nov 11, 2008 216) Antibiotic Resistance in the ICU: How We Got Here and Where Are We Going? Multispecialty Grand Rounds. Altru Medical Center, University of North Dakota (Grand Forks, ND) Jan 7, 2009 217) Lessons from the Manitoba Septic Shock Database: Local Epidemiologic and Treatment Trends. Medical Grand Rounds. Health Sciences Centre, University of Manitoba (Winnipeg, MB) Jan 27, 2009 218) An Alternate Injury Paradigm for Sepsis and Septic Shock and its Implications for Antimicrobial Therapy. Society of Critical Care Medicine Annual Refresher Course (Nashville, TN) Jan 31, 2009. 219) Monotherapy vs Combination Antimicrobial Therapy of Sepsis and Septic Shock: Combination Therapy Yields Improved Outcome. Society of Critical Care Medicine Annual Scientific Symposium (Nashville, TN) Feb 3, 2009

72

220) Speed is Life: Optimizing Antimicrobial Management of Septic Shock. Society of Critical Care Medicine Annual Scientific Symposium (Nashville, TN) Feb 4, 2009 221) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Academy of Infection Management Symposium. Metropole Hotel (London, England) March 16, 2009 222) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Wales Hospital (Cardiff, England) March 17, 2009 223) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Southampton Hospital (Southampton, England) March 17, 2009 224) Combination Therapy: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Western General Hospital (Edinburgh, England) March 18, 2009 225) Optimizing Outcomes: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Manchester University, Wythenshaw Hospital (Manchester, England) March 19, 2009 226) Septic Shock: Optimizing Source Control. Surgical Grand Rounds, Health Sciences Centre, University of Manitoba (Winnipeg, MB) April 2, 2008 227) Optimizing Therapy of Life-Threatening Candida Infections. Astellas Advisory Meeting (Montreal, QC) April 17, 2008 228) Getting it Right, Right Now. Optimizing Outcome in Septic Shock. McGill Critical Care Symposium (Montreal, QC) April 24, 2008 229) Preventing ICU Infections. McGill Critical Care Symposium (Montreal, QC) April 24, 2008 230) Septic Shock: Manitoba Epidemiologic and Treatment Trends. Edge of Excellence Conference (Winnipeg, MB) May 11, 2009 231) Optimizing Antimicrobial Therapy in Septic Shock: Code Sepsis: Sepsis syndromes and life-saving therapies. American Society of Microbiology 109th General Meeting (Philadelphia, PA) May 20, 2009 232) H1N1 Infection in ICU. Canadian Pandemic Preparedness Meeting: H1N1 Outbreak Research Response (Toronto, ON) July 8, 2009

73

233) Severe H1N1 In Manitoba ICUs. Canadian Pandemic Preparedness Meeting: H1N1 Outbreak Research Response (Toronto, ON) July 8, 2009 234) Antimicrobial Use in the ICU. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 15, 2009 235) Multi-resistant Infections. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 15, 2009 236) Infections in AIDS, Transplant Patients and other Immunocompromised Hosts. Multiprofessional Critical Care Review Course 2009 (San Francisco, CA) July 16, 2009 237) Lessons from the ICU: The Winnipeg H1N1 Outbreak. Ottawa CME Telecast/Manitoba TeleHealth Service (Winnipeg, MB) July 29, 2009 238) Severe Disease Epidemic Narratives: Description of Clinical Management and Challenges Experienced in Winnipeg ICUs. PHAC Conference: Severe H1N1 Disease: Preventing Cases, Reducing Mortality. (Winnipeg, MB) Sept 2, 2009 239) Adjunctive therapies –what do you have left when oseltamivir fail. PHAC Conference: Severe H1N1 Disease: Preventing Cases, Reducing Mortality. (Winnipeg, MB) Sept 3, 2009 240) Severe H1N1 Infection in the ICU. H1N1 Mini-symposium. Weimar Sepsis Update: Sepsis Goes Public. 4th International Congress on Sepsis and Mult-iorgan Dysfunction. (Weimar, Germany) Sept 9, 2009 241) Strategies to prevent antibiotic delays. Rationale use of antibiotics in sepsis. Weimar Sepsis Update: Sepsis Goes Public. 4th International Congress on Sepsis and Multi-organ Dysfunction. (Weimar, Germany) Sept 10, 2009 242) H1N1: Description of Clinical Management and Challenges Experienced in Winnipeg ICUs. Primera Pandemia de Gripe en UCIs, Sociedad Espanola de Medicina Intensiva, Critica y Unidades Coronarias (Madrid, Spain) Oct 5, 2009 243) Severe H1N1 Infection in Canada. Primera Pandemia de Gripe en UCIs, Sociedad Espanola de Medicina Intensiva, Critica y Unidades Coronarias (Madrid, Spain) Oct 5, 2009

244) Speed is Life: Optimizing Antimicrobial Management of Septic Shock. Critical Care Grand Rounds, Servicio de Medicina Intensiva y Crítica Hospital Universitari de Tarragona Joan XXIII (Tarragona, Spain) October 6, 2009

74

245) H1N1: Description of Clinical Management and Challenges Experienced in Winnipet ICUs, Servicio de Medicina Intensiva y Crítica Hospital Universitari de Tarragona Joan XXIII (Tarragona, Spain) October 7, 2009 246) ICU Management of Severe H1N1 Infection. WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza (Washington, DC) October 14, 2009 247) Epidemiology of Septic Shock in Canada. Critical Care Canada Forum (Toronto, ON) October 26, 2009 248) Fungal Septic Shock. Critical Care Canada Forum (Toronto, ON) October 26, 2009 249) Diagnosis and Management of Fungal Sepsis. Critical Care Canada Forum (Toronto, ON) October 26, 2009 250) Pathology of Severe H1N1 Infection. Critical Care Canada Forum (Toronto, ON) October 27, 2009 251) Fungal Sepsis and Septic Shock. Critical Care Canada Forum (Toronto, ON) October 27, 2009 252) The Right Antibiotic at the Right Time. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 11, 2009 253) Current Evidence: Monotherapy vs Combination Therapy in Septic Shock. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 11, 2009 254) Myocardial Dysfunction in Sepsis and Septic Shock: Diagnosis and Treatment. Brazilian Congress of Critical Care Medicine (Sao Paulo, Brazil) Nov 12, 2009 254) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. St. George’s Hospital (South London, England) Dec 14, 2009 254) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. British Intensive Care Society Annual Meeting (London, England) Dec 14, 2009 254) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Sheffield Hallam Teaching Hospital (Sheffield, England) Dec 15, 2009 255) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Aberdeen Royal Infirmary (Aberdeen, Scotland) Dec 16,

75

2009 256) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University of Glasgow Medical School (Glasgow, Scotland) Dec 16, 2009 257) Speed is Life: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. University College (London) Hospital (London, England) Dec 17, 2009 258) Optimizing Outcomes in Septic Shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. King’s College Hospital (London, England) Dec 17, 2009 257) How research is driving clinical outcomes / tales from the front lines of the H1N1 epidemic. Manitoba Health Research Council Presentation. Manitoba Legislature (Winnipeg, MB) Feb 16, 2010 258) Lessons from the frontlines of the H1N1 pandemic. American Thoracic Society State of the Art Review Course. (Miami, FL) Feb 26, 2010 259) My experience with H1N1. 30th International Symposium on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 9, 2010 260) ECMO in H1N1-associated respiratory failure. 30th International Symposium on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 10, 2010 261) Antimicrobials in septic shock. 30th International Symposium on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 10, 2010 262) Antibiotic therapy: Optimal timing. 30th International Symposium on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 11, 2010 263) Improving sepsis management: Speed is life. 30th International Symposium on Intensive Care and Emergency Medicine. (Brussels, Belgium) March 11, 2010 264) Unilateral Withdrawal: An 11th Commandment? Canadian Critical Care Conference (Whistler, BC) March 18, 2010 265) Panelist. Lessons from the H1N1 Pandemic in Canada. Canadian College of Health Service Executives/Health Professional’s Roundtable for Strategy Meeting. (New York, NY) April 15, 2010 266) Lessons from the Manitoba H1N1 Epidemic. The Critical Eye Nursing Conference. McPhillips Street Station. (Winnipeg, MB) April 19, 2010

76

267) Lessons from the Manitoba H1N1 epidemic. Roche Medical Advisory Board Meeting (Toronto, ON) April 19, 2010 268) Pandemic H1N1: From the front lines of the Winnipeg ICUs. Pan-infORM Workshop: The First Influenza Pandemic of the 21st Century: Canada's Response, Lessons Learned, and Challenges Ahead. National Biodiagnostics Institute (Winnipeg, MB) April 19, 2010 269) Speed is life: The role of rapid, appropriate antimicrobial therapy in outcome of septic shock. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 14, 2010. 270) Speed is life but a sledgehammer helps too: The importance of early pharmacokinetic/pharmacodynamic optimization in outcome of septic shock. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 14, 2010. 271) Pandemic H1N1: Lessons learned in the ICU. XLV Congresio Nationale de la SEMICYUC 2010. SEMICYUC:Spanish National Critical Care Society (Malaga, Spain) June 15, 2010. 272) H1N1 2009: The ICU Perspective. 50th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (Boston, MA) Sept 12, 2010 273) Antimicrobial optimization in sepsis and septic shock. Pulmonary-Critical Care Grand Rounds, Wake-Forest University School of Medicine (Winston-Salem, NC) Oct 20, 2010 275) Optimizing outcomes in septic shock: Lessons from the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database. Moses-Cone Annual Critical Care Symposium: A Day of Critical Care (Greensboro, NC) Oct 21, 2010. 275) Mission Possible: “Killing bugs, disarming messengers”—Optimizing outcomes in sepsis with evidence-based antimicrobial therapy. Infectious Diseases Society of America Satellite Symposium (IDSA) (Vancouver, BC) Oct 22, 2010.

276) Monotherapy vs. combination therapy of sepsis. Advanced Course on ICU Infections. Winthrop University Hospital and Weill-Cornell Medical Center (New York, NY) Oct 25, 2010. 278) Speed is life: Optimizing antimicrobial therapy in septic shock. Symposium: Severe Sepsis Treatment: Is it Time? American College of Chest Physicians Annual Symposium (Vancouver, BC) Oct 31, 2010

77

279) Monotherapy vs combination therapy in septic shock. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 280) Speed is life but a hammer helps too. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 281) Pandemic H1N1: Lessons learned. Critical Care Canada Forum (Toronto, ON) Nov 8, 2010 282) Early pharmacokinetic/pharmacodynamic optimization of antimicrobials in the outcome of septic shock. Critical Care Canada Forum (Toronto, ON) Nov 10, 2010 283) Pandemic H1N1 Influenza: Lessons learned. Society of Critical Care Medicine Annual Refresher Course (San Diego, CA) Jan 14, 2011 284) Septic shock: why antimicrobial therapy matters. Society of Critical Care Medicine Annual Refresher Course (San Diego, CA) Jan 14, 2011 285) Sepsis and septic shock: State of the art. 16th International Symposium on Infections in the Critically Ill (Porto, Portugal) Feb 24, 2011 286) The need for early antimicrobial therapy in septic shock. 16th International Symposium on Infections in the Critically Ill (Porto, Portugal) Feb 25, 2011 287) Rational antibiotic use in the critically ill. American Thoracic Society State of the Art Annual Meeting (San Diego, CA) March 3, 2011 288) Meet the Professor. American Thoracic Society State of the Art Annual Meeting 2011 (San Diego, CA) March 3, 2011 289) Lessons from the Cooperative Antimicrobial Therapy of Septic Shock Database. Section of Critical Care Medicine, University of Manitoba, Research in Progress (Winnipeg, MB) March 16, 2011 290) The importance of timing of therapies in septic shock. American Thoracic Society Annual Scientific Symposium 2011 (Denver, CO) May 15, 2011 291) Hit hard and fast: Mono vs combination therapy. German Sepsis Society Meeting (Weimar, Germany) Sept 9, 2011 292) How I de-escalate antimicrobial therapy. German Sepsis Society Meeting (Weimar, Germany) Sept 9, 2011. 293) Critical care delivery in the 2009 influenza pandemic: practical lessons from Manitoba, Canada. In the Symposium: Influenza antivirals -new insights on disease

78

management and control. 4th ESWI (European Scientific Working Group on Influenza) Conference (St. George’s Bay, Malta) Sept 13, 2011. 294) Speed is Life: Optimizing antimicrobial therapy in septic shock. American College of Chest Physicians Annual Scientific Symposium (Honolulu, Hawaii) Oct 24, 2011 295) Speed is life but a hammer helps too. New concepts in optimizing antimicrobial therapy in septic shock. Sepsis Congress India 2011 (New Delhi, India) Nov 11, 2011 296) Viral pneumonia management, Focus on pandemic H1N1 2009. Sepsis Congress India 2011 (New Delhi, India) Nov 12, 2011 297) Optimizing antimicrobial therapy of fungal sepsis/septic shock. Sepsis Congress India 2011 (New Delhi, India) Nov 12, 2011 298) Speed is Life: Optimizing antimicrobial therapy in septic shock. 38th Annual Critical Care Symposium (Portland, OR) Nov 16, 2011 299) A Hammer Helps Too: Optimizing outcomes by maximizing pathogen clearance in septic shock. 38th Annual Critical Care Symposium (Portland, OR) Nov 16, 2011 300) Optimizing Antimicrobials in Septic Shock (the Laboratory Program). Section of Critical Care Medicine, University of Manitoba, Research in Progress (Winnipeg, MB) Nov 24, 2011 301) Speed is life but a hammer helps too. New concepts in optimizing antimicrobial therapy in septic shock. Department of Medicine, University of Manitoba Grand Rounds (Winnipeg, MB) Dec 6, 2011 302) Optimizing Antimicrobials in Septic Shock (the Laboratory Program). Section of Infectious Diseases/Medical Microbiology, University of Manitoba, Research in Progress (Winnipeg, MB) Dec 15, 2011 303) Speed is Life: Optimizing antimicrobial therapy in septic shock. Victoria General Hospital (Winnipeg, MB) Jan 30, 2012 304) Speed is life: The role of rapid, appropriate antimicrobial therapy in outcome of septic shock. 8th Annual Perioperative Medicine Meeting (Madrid, Spain) Feb 17, 2012 305) Speed is life but a sledgehammer helps too: The importance of early pharmacokinetic/ pharmacodynamic optimization in outcome of septic shock. 8th Annual Perioperative Medicine Meeting (Madrid, Spain) Feb 17, 2012 306) Optimization of antimicrobial therapy of septic shock: Hit hard and fast! German Anesthesiology Congress 2012 (Leipzig, Germany) May 6, 2012

79

307) Optimization of antimicrobial therapy of septic shock. Special Symposium on Infection in the ICU: What it important? (Berlin, Germany) May 7, 2012 308) Optimization of antimicrobial therapy of septic shock: Speed is life. Update on Sepsis 2012. University Clinic, Eppendorf (Hamburg, Germany) May 8, 2012 309) A sledgehammer helps too: Optimizing antimicrobial therapy in septic shock. Lebensbedrohliche Infektionen. (Dusseldorf, Germany) May 9, 2012 310) Optimization of antimicrobial therapy for septic shock. Hit hard and hit fast. Colloquium on Infection Control and Therapy. University of Heidelberg Clinic (Heidelberg, Germany) May 10, 2012 311) Optimization of antimicrobial therapy for septic shock. Hit hard and hit fast. Colloquium on Infection Control and Therapy: Bridging the Gap. (Frankfurt, Germany) May 11, 2012. 312) Optimization of antimicrobial therapy of septic shock. Infektiologie Update (Munich, Germany) May 12, 2012. 313) Optimizing antimicrobial therapy in septic shock. Hit hard and fast. Tuscany Critical Care Society Annual Meeting (Florence, Italy) June 13, 2012 314) Combination antibiotics and outcome of life-threatening bacterial Infections and septic shock. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA) Sept 10, 2012 315) Treatment and outcome of septic shock in Winnipeg. Symposium on Treatment of Severe Infections and De-escalation Strategy of Antimicrobial Therapy (Winnipeg, MB) Sept 18, 2012 316) Therapy of sepsis. Symposium on Treatment of Severe Infections and De-escalation Strategy of Antimicrobial Therapy (Winnipeg, MB) Sept 18, 2012 317) Speed is life: Time matters in management of septic shock. American College of Chest Physicians Annual Scientific Symposium (Atlanta, Georgia) Oct 24, 2012 318) Infections in immunosuppressed patients. 30th Chilean Critical Care Conference (La Serena, Chile) Oct 25, 2012 319) Speed is life: the importance of early antimicrobial initiation in septic shock. 30th Chilean Critical Care Conference (La Serena, Chile) Oct 25, 2012

80

320) A hammer helps: the role of dose, pharmacokinetics and drug combinations in septic shock. 30th Chilean Critical Care Conference (La Serena, Chile) Oct 26, 2012 321) Antimicrobial De-escalation. 30th Chilean Critical Care Conference (La Serena, Chile) Oct 26, 2012 322) The role of rapid source control in management of septic shock. Critical Care Canada Forum (Toronto, ON) Oct 29, 2012 323) Why delays of antimicrobial therapy delivery occur and how to correct them. Critical Care Canada Forum (Toronto, ON) Oct 31, 2012 324) Immune defects and infection risk: How to assess. Society of Critical Care Medicine Annual Scientific Symposium (San Juan, Puerto Rico) Jan 21, 2013 325) Optimizing antimicrobial therapy of septic shock: Speed is life. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 326) Candida Sepsis: Speed is life. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 327) Optimizing antimicrobial therapy of septic shock: A hammer helps too. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 328) Early goal directed therapy: Controversies and newer trials. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 1, 2013 329) Myocardial depression in sepsis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 2, 2013 330) Clinical research in critical care: How to get started. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 2, 2013 331) Antimicrobial de-escalation in the infected ICU patient. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 3, 2013 332) How to perform a meta-analysis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 4, 2013 333) Assessing a meta-analysis. Indian Society of Critical Care Medicine Annual Meeting (Kolkata, India) March 5, 2013 334) Speed is life: Optimizing antimicrobial therapy of septic shock. Ruby Hall Clinic and Hospital (Pune, India) March 6, 2013

81

335) Speed is life: Optimizing antifungal therapy in candida septic shock. Lilavati Hospital & Research Centre (Mumbai, India) March 7, 2013 336) Speed is life: Optimizing antimicrobial therapy of septic shock. Tagore Hospital (Chennai, India) March 8, 2013 337) Speed is life: Optimizing antifungal therapy in candida septic shock. Apollo Hospital (Hyderabad, India) March 11, 2013 338) Speed is life: Optimizing antimicrobial therapy of septic shock. Mediciti Hospital (Hyderabad, India) March 11, 2013 339) Speed is life: Optimizing antifungal therapy in candida septic shock. Sir Gangaram Hospital (Delhi, India) March 12, 2013 340) Speed is life: Optimizing antimicrobial therapy of septic shock. Medanta Medicity Hospital (Delhi, India) March 12, 2013 341) Speed is life: Optimizing antimicrobial therapy of septic shock. Apollo Hospital (Ludhiana, India) March 13, 2013 342) Visionary Conversations: Global pandemic: Another Y2K or future apocalypse? University of Manitoba Medical School (Winnipeg, MB) April 17, 2013 343) Optimizing antimicrobial therapy in septic shock. British Columbia Sepsis Network (Vancouver, BC) April 23, 2013 344) Optimizing antimicrobial therapy in septic shock. Windsor Respirology Update 2013 (Windsor, ON) April 25, 2013 345) Antimicrobial de-escalation in ICU. Winnipeg Regional Health Authority (WRHA) Critical Care Improvement Symposium (Winnipeg, MB) May 23, 2013 346) Optimizing antimicrobial therapy of septic shock. Calgary Critical Care Medicine Grand Grounds (Calgary, AB) May 29, 2013 347) Antibiotic De-escalation Strategies in the Critically Ill Infected Patient. 10the Sydney Short Course in Intensive Care Medicine (Sydney, Australia) July 24, 2013 348) Optimizing PK/PD antimicrobial parameters in critically ill patients with septic shock. Clinical Infectious Diseases Forum (Sydney, Australia) July 26, 2013 349) Strategies for achieving de-escalation of antimicrobial therapy in the critically ill. Clinical Infectious Diseases Forum (Sydney, Australia) July 27, 2013

82

350) The rationale for maximizing cidality in antimicrobial treatment of septic shock. Clinical Infectious Diseases Forum (Sydney, Australia) July 27, 2013 351) Causes and consequences of delays in appropriate antimicrobial therapy of septic shock. Royal Adelaide Hospital Medical Grand Rounds (Adelaide, Australia) July 29, 2013 352) When is combination Gram negative cover appropriate for critically ill patients? Australasian Society for Infectious Diseases. Gram Negative "Superbugs" Meeting 2013 (Gold Coast, Australia) August 2, 2013 353) Speed is life: Optimizing delivery of antimicrobial therapy in septic shock. Infectious Diseases Symposium, Westmead Hospital (Sydney, Australia) August 8, 2013 354) Combination antimicrobial therapy is unwarranted for gram positive and negative nosocomial sepsis. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 29, 2013 355) Antibiotics: an update. Optimizing pharmacokinetics. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013 356) Epidemics: H1N1, lessons learned. World Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013 357) Combination therapy for GNI: a better outcome? Federation of Societies of Intensive and Critical Care Medicine 2013 Meeting, Durban Convention Center (Durban, South Africa) Aug 30, 2013 358) Empirical antimicrobial therapy - combo vs. mono, combo is better. 6th International Congress of the German Sepsis Society (Weimar, Germany) Sept 5, 2013 359) Optimization of antimicrobial therapy in the context of septic shock – Hit hard and fast. 6th International Congress of the German Sepsis Society (Weimar, Germany) Sept 6, 2013 360) Why time matters: The role of urgency in treating sepsis. American College of Chest Physicians Annual Symposium (Chicago, IL) Oct 28, 2013 361) CVP is adequate for volume administration in sepsis. American College of Chest Physicians Annual Symposium (Chicago, IL) Oct 30, 2013

83

362) Optimization of antimicrobial therapy in the context of septic shock: Hit hard and fast. 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 7, 2013 363) Pharmacokinetic considerations in antimicrobial management of septic shock. Hit hard and fast. 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 7, 2013 364) Early antimicrobial therapy in nosocomial infections. When should it be fast? 18th Brazilian Congress of Intensive Care Medicine (Rio de Janeiro, Brazil) Nov 8, 2013 365) EGT: Newer trials, newer controversies. Canadian Critical Care Forum. (Toronto, ON) Nov 10, 2013 366) Assessing immune defects and infection risk. Canadian Critical Care Forum. (Toronto, ON) Nov 11, 2013 367) Lessons from the ICU: The Canadian H1N1 pandemic. Canadian Critical Care Forum. (Toronto, ON) Nov 12, 2013 368) Improving survival in septic shock patients through optimizing antimicrobial therapy. McGill Critical Care Medicine Grand Rounds. Montreal General Hospital. (Montreal, QC) Nov 29, 2013 369) Research in Septic Shock: Bench to Bedside. Critical Care Fellow Seminar. Montreal General Hospital (Montreal, QC) Nov 29, 2013 370) Optimizing antimicrobial therapy in septic shock: Speed is life. 52nd Annual Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 4, 2014 371) Optimizing antimicrobial therapy in septic shock. A hammer helps too. 52nd Annual Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 5, 2014 372) Antimicrobial De-escalation…can it improve outcome? 52nd Annual Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 5, 2014 373) Update on influenza: 2014. 52nd Annual Weil/University of California Symposium on Critical Care and Emergency Medicine. (Las Vegas, Nevada) April 6, 2014 374) Ebola and Other Hemorrhagic Fevers. City-wide Anesthesia Grand Rounds. University of Manitoba (Winnipeg, MB) September 3, 2014

84

375) Appropriate Anti-Infective Therapy in the ICU: Can We Do Better? 54th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Symposium (Washington, DC) September 8, 2014 376) Update in Septic Shock in Trauma Patients. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 18, 2014 377) The Heart in Sepsis. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 18, 2014 378) Optimizing Antimicrobials in Obese and Elderly Patients. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 19, 2014 379) Inotrope Selection in Septic Shock. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 20, 2014 380) AKI in Patients with Septic Shock. Diagnosis and Treatment. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 20, 2014 381) Obese Patients with Sepsis: Clinical Characteristics and Outcome. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 21, 2014 382) Importance of PK/PD Aspects of Antimicrobial Therapy in Septic Shock. 24th Argentinian Congress on Intensive Therapy (Mar del Plata, Argentina) September 21, 2014 383) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. The 10th Annual Infectious Diseases/Critical Care Pharmacotherapy Conference on Contemporary Issues in the Management of Infections (Toronto, ON) Sept 27, 2014 384) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock II. University of Toronto Continuing Medical Education (Toronto, ON) Sept 28, 2014 385) Monitoring Volume Status and Giving Fluids After Early Goal-Directed Therapy. American College of Chest Physicians Annual Scientific Symposium (Austin TX) Oct 26, 2014 386) Antimicrobials: Nothing Else Matters. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2014 387) The ROSII RCT - Low vs. High-Dose Oseltamivir in H1N1. Canadian Critical Care Forum (Toronto, ON) Oct 30, 2014

85

388) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Antimicrobial Stewardship: Current Challenges and Concerns Biomedis CME (Cebu City, Philippines) Nov 7, 2014 389) Optimizing Antimicrobial Therapy in Sepsis and Septic Shock. Antimicrobial Stewardship: Current Challenges and Concerns Biomedis CME (Manila, Philippines) Nov 9, 2014 390) Optimizing antimicrobial therapy in septic shock: Speed is life. University of Washington Medicine Regional Sepsis Conference (Seattle, WA) March 6, 2015 391) Optimizing antimicrobial therapy in septic shock: A hammer helps too. University of Washington Medicine Regional Sepsis Conference (Seattle, WA) March 6, 2015 392) Heterogeneity in Sepsis: Pathogen and Infection Site. American Thoracic Society Annual International Conference (Denver, CO) May 17, 2015